

HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2023 OF THE CONDITION AND AFFAIRS OF THE

Anthem Health Plans of Maine, Inc.

NAIC Group C		C Company Code	e <u>52618</u> Employer's ID	Number 31-1705652
Organized under the Laws of	Maine	, s	State of Domicile or Port of En	try ME
Country of Domicile		United States	of America	
Licensed as business type:		Othe	r	
Is HMO Federally Qualified? Yes [] No [X]			
Incorporated/Organized	03/10/2000		Commenced Business	06/05/2000
Statutory Home Office	the Laws of Maine State of Domicile or Port of Entry MBE United States of America		th Portland, ME, US 04106-6911	
	(Street and Number)		(City or	Town, State, Country and Zip Code)
Main Administrative Office				
South Portla	and, ME, US 04106-6911	(Street and r	Number)	866-583-6182
(City or Town, S	State, Country and Zip Code)		(Ar	rea Code) (Telephone Number)
		,		
Primary Location of Books and Record	ds	220 Virginia	Avenue	
•				000 004 4470
			(Ar	
Internet Website Address		www.elevancel	nealth.com	
Statutory Statement Contact	Loigh Barrett			317 /32 6088
Statutory Statement Contact				(Area Code) (Telephone Number)
(-		OFFICE	-00	(1.01.1.0.1)
President and Chairperson	Denise Finn McDonough	OFFICE		Vincent Edward Scher
•				
		OTHE	:R	
Laura Sanborn, Assistant	Secretary			
Danica Fina MaDan				Kethleen Cueen Kiefer
				David Mark Jaffe #
Scott Wayne Angl	in #			
State of II	ndiana			
all of the herein described assets we statement, together with related exhibicondition and affairs of the said report in accordance with the NAIC Annual rules or regulations require difference respectively. Furthermore, the scope exact copy (except for formatting difference to the enclosed statement of	The the absolute property of the said ts, schedules and explanations there in gentity as of the reporting period s Statement Instructions and Accounting the sin reporting not related to accord this attestation by the described rences due to electronic filing) of the Managara.	reporting entity, fin contained, and tated above, and ng Practices and bunting practices officers also incluenclosed statem Docusign D85175E Katnieen Sus	free and clear from any liens nexed or referred to, is a full at of its income and deductions Procedures manual except to and procedures, according des the related corresponding ent. The electronic filing may need by:	or claims thereon, except as herein stated, and that this nd true statement of all the assets and liabilities and of the therefrom for the period ended, and have been completed the extent that: (1) state law may differ; or, (2) that state to the best of their information, knowledge and belief, g electronic filing with the NAIC, when required, that is an be requested by various regulators in lieu of or in addition DocuSigned by: Vincent & Scher A85A33722D4143E
Subscribed and sworn to before me the 25th day of Janua Louanna Stiner			b. If no, 1. State the amendme	ent number

06/29/31

LOUANNA STINER Notary Public - Seal Marion County - State of Indiana Commission Number 190749866 My Commission Expires Jun 29, 2031

ASSETS

			Prior Year		
		1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
1.	Bonds (Schedule D)			296,631,138	389,337,511
2.	Stocks (Schedule D):				
	2.1 Preferred stocks			0	0
	2.2 Common stocks			0	0
3.	Mortgage loans on real estate (Schedule B):				
	3.1 First liens			0	0
	3.2 Other than first liens			0	0
4.	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less \$0				
	encumbrances)	9,541		9,541	11,926
	4.2 Properties held for the production of income (less				
	\$0 encumbrances)			0	0
	4.3 Properties held for sale (less \$0				
	encumbrances)			0	0
5.	Cash (\$(59,839), Schedule E - Part 1), cash equivalents				
	(\$0 , Schedule E - Part 2) and short-term				
	investments (\$0 , Schedule DA)	(59,839)		(59,839)	6,901,785
6.	Contract loans, (including \$ premium notes)			0	0
7.	Derivatives (Schedule DB)			0	0
8.	Other invested assets (Schedule BA)			0	0
9.	Receivables for securities			0	0
10.	Securities lending reinvested collateral assets (Schedule DL)	10,441,966		10,441,966	15,664,442
11.	Aggregate write-ins for invested assets	0	0	0	0
12.	Subtotals, cash and invested assets (Lines 1 to 11)	307,022,806	0	307,022,806	411,915,664
13.	Title plants less \$ charged off (for Title insurers				
	only)			0	0
14.	Investment income due and accrued	1,692,264		1,692,264	2,389,561
	Premiums and considerations:				
	15.1 Uncollected premiums and agents' balances in the course of collection	26,513,718	859,557	25,654,161	29,935,023
	15.2 Deferred premiums, agents' balances and installments booked but				
	deferred and not yet due (including \$ 37,726,183				
	earned but unbilled premiums)	37,726,183		37,726,183	36,844,345
	15.3 Accrued retrospective premiums (\$ 681,941) and				
	contracts subject to redetermination (\$ 102,463)	784,404		784,404	3,201,585
16.	Reinsurance:				
	16.1 Amounts recoverable from reinsurers				0
	16.2 Funds held by or deposited with reinsured companies				0
	16.3 Other amounts receivable under reinsurance contracts				
	Amounts receivable relating to uninsured plans				
	Current federal and foreign income tax recoverable and interest thereon \dots				
18.2	Net deferred tax asset			0	0
	Guaranty funds receivable or on deposit				
20.	Electronic data processing equipment and software			0	0
21.	Furniture and equipment, including health care delivery assets				
	(\$)				
	Net adjustment in assets and liabilities due to foreign exchange rates				
	Receivables from parent, subsidiaries and affiliates				
	Health care (\$38,895,612) and other amounts receivable				
	Aggregate write-ins for other than invested assets	58,584,718	2,033,105	56,551,613	57,998,038
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	504 283 050	50 660 622	543 614 331	740 507 052
27	From Separate Accounts, Segregated Accounts and Protected Cell				140,301,332
27.	Accounts			0	0
28.	Total (Lines 26 and 27)	594,283,959	50,669,628	543,614,331	740,507,952
	DETAILS OF WRITE-INS				
1101.					
1102.					
1103.					
	Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0
	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0		0
	Federal Employee Program assets held by agent	51.580.259		51 580 259	55.438.580
	State income tax receivable				
	Premium tax recoverable				
	Summary of remaining write-ins for Line 25 from overflow page	,		· ·	
	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	58,584,718			
_000.	Totalo (Ellico 2001 tilla 2000 piuo 2000/(Ellic 20 abuve)	00,004,710	2,000,100	00,001,010	01,000,000

LIABILITIES, CAPITAL AND SURPLUS

	LIADILITIES, CAF	., ,	Current Year		Prior Year
		1	2	3	4
		'	-		·
		Covered	Uncovered	Total	Total
1.	Claims unpaid (less \$	141,829,160	660,079	142,489,239	170,833,550
2.	Accrued medical incentive pool and bonus amounts	1,387,425		1,387,425	1,287,677
3.	Unpaid claims adjustment expenses			3,583,051	3,566,155
4.	Aggregate health policy reserves, including the liability of	, ,		, ,	, ,
	\$				
		104 000 450		104 000 450	100 070 000
	Health Service Act				
5.	Aggregate life policy reserves				
6.	Property/casualty unearned premium reserves			0	0
7.	Aggregate health claim reserves			0	0
8.	Premiums received in advance	18,283,698		18,283,698	15,861,143
9.	General expenses due or accrued				
10.1					10,401,200
10.1	. ,			0	0
	(including \$ on realized capital gains (losses))				
10.2	Net deferred tax liability				
11.	Ceded reinsurance premiums payable	12,936		12,936	9,631
12.	Amounts withheld or retained for the account of others	319,393		319,393	1,392,381
13.	Remittances and items not allocated	12,630,229		12,630,229	16,645,942
14.	Borrowed money (including \$ current) and	, ,		, ,	
14.	,				
	interest thereon \$ (including				
	\$ current)				
15.	Amounts due to parent, subsidiaries and affiliates	' '			, ,
16.	Derivatives			0	0
17.	Payable for securities			0	0
18.	Payable for securities lending				
19.	Funds held under reinsurance treaties (with \$				
19.	,				
	authorized reinsurers, \$0 unauthorized				
	reinsurers and \$0 certified reinsurers)			0	0
20.	Reinsurance in unauthorized and certified (\$				
	companies			0	0
21.	Net adjustments in assets and liabilities due to foreign exchange rates			0	0
22.	Liability for amounts held under uninsured plans				72 692 007
					12,002,001
23.	Aggregate write-ins for other liabilities (including \$				
	current)				
24.	Total liabilities (Lines 1 to 23)	408,096,162	660,079	408,756,241	586,880,724
25.	Aggregate write-ins for special surplus funds	XXX	XXX	4,614,863	5,903,698
26.	Common capital stock	XXX	XXX	2,500,000	2,500,000
27.	Preferred capital stock	XXX	XXX		
	Gross paid in and contributed surplus				
28.					
29.	Surplus notes				
30.	Aggregate write-ins for other than special surplus funds				
31.	Unassigned funds (surplus)	XXX	XXX	7,090,327	24,570,630
32.	Less treasury stock, at cost:				
	32.1 shares common (value included in Line 26				
	\$	YYY	YYY		
	·				
	32.2 shares preferred (value included in Line 27				
	\$				
33.	Total capital and surplus (Lines 25 to 31 minus Line 32)	XXX	XXX	134,858,090	153,627,228
34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	543,614,331	740,507,952
	DETAILS OF WRITE-INS				
2301	Escheat liability	1 718 548		1 718 548	1 953 183
	·				
2302.	Other liabilities				
2303.	Other premium liability				
2398.	Summary of remaining write-ins for Line 23 from overflow page	212,945	0	212,945	513,295
2399.	Totals (Lines 2301 thru 2303 plus 2398)(Line 23 above)	4,402,251	0	4,402,251	5,808,418
2501.	Deferred gain on sale-leaseback transaction	XXX	XXX	4,614,863	5,903,698
2502.	9				
	Summary of remaining write-ins for Line 25 from overflow page				0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	XXX	XXX	4,614,863	5,903,698
3001.		xxx	XXX		
	Summary of remaining write-ins for Line 30 from overflow page				
3099.	Totals (Lines 3001 thru 3003 plus 3098)(Line 30 above)	XXX	XXX	0	0

STATEMENT OF REVENUE AND EXPENSES

	STATEMENT OF REVENUE AN			
		Current 1	Year 2	Prior Year 3
		Uncovered	Total	Total
1.	Member Months	xxx	3,847,998	4,518,984
2.	Net premium income (including \$ non-health premium income)	XXX	1,218,705,924	1,207,401,954
3.	Change in unearned premium reserves and reserve for rate credits	xxx	31 171 052	(5 387 893)
4.	Fee-for-service (net of \$ medical expenses)			
5.	Risk revenue			
6.	Aggregate write-ins for other health care related revenues			
7.	Aggregate write-ins for other non-health revenues	XXX	0	0
8.	Total revenues (Lines 2 to 7)	XXX	1,249,876,976	1,202,014,061
	Hospital and Medical:			
9.	Hospital/medical benefits	18,529,355	720,873,672	706,311,763
10.	Other professional services	4,287,181	71,935,978	71,816,385
11.	Outside referrals		12,593,290	13,788,046
12.	Emergency room and out-of-area	968 . 133	79.879.836	71.831.168
13.	Prescription drugs			
	Aggregate write-ins for other hospital and medical			
14.				
15.	Incentive pool, withhold adjustments and bonus amounts			
16.	Subtotal (Lines 9 to 15)	25,280,738	1 , 106 , 196 , 855	1,054,072,470
	Less:			
17.	Net reinsurance recoveries			·
18.	Total hospital and medical (Lines 16 minus 17)	25,280,738	1,106,398,504	1,053,915,609
19.	Non-health claims (net)			
20.	Claims adjustment expenses, including \$16,800,830 cost containment expenses			
21.	General administrative expenses			66,656,142
22.	Increase in reserves for life and accident and health contracts (including \$, ,
	increase in reserves for life only)		0	0
23.	Total underwriting deductions (Lines 18 through 22)			
24.	Net underwriting gain or (loss) (Lines 8 minus 23)			
25.	Net investment income earned (Exhibit of Net Investment Income, Line 17)			
26.	Net realized capital gains (losses) less capital gains tax of \$		(7, 187, 466)	(102,846)
27.	Net investment gains (losses) (Lines 25 plus 26)	0	5,592,518	10,488,147
28.	Net gain or (loss) from agents' or premium balances charged off [(amount recovered			
	\$		(238,915)	(225,280)
29.	Aggregate write-ins for other income or expenses	0	(2.923.651)	739.834
30.	Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus		(2,020,00.7	
30.	27 plus 28 plus 29)	XXX	43,671,707	54,357,367
31.	Federal and foreign income taxes incurred	XXX	9,847,846	(993,635)
32.	Net income (loss) (Lines 30 minus 31)	XXX	33,823,861	55,351,002
02.		7000	30,020,00.	00,00:,002
0004	DETAILS OF WRITE-INS	VVV		
0601.				
0602.				
0603				
0698.	Summary of remaining write-ins for Line 6 from overflow page			
0699.	Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above)	XXX	0	0
0701.				
0702.				
0703				
0798.	Summary of remaining write-ins for Line 7 from overflow page	XXX	0	0
0799.	Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above)	XXX	0	0
1401.				
1402.				
1403.				
1498.	Summary of remaining write-ins for Line 14 from overflow page	0	0	0
1499.	Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above)	0	0	0
2901.	Miscellaneous income		2,076,349	739,834
2902.	Regulatory penalty		(5,000,000)	
2903				
2998.	Summary of remaining write-ins for Line 29 from overflow page			0
2999.	Totals (Lines 2901 thru 2903 plus 2998)(Line 29 above)	0	(2,923,651)	739,834
_555.	. State (2.1.30 200) till a 2000 pido 2000/(Elito 20 above)	<u> </u>	(2,520,501)	700,004

STATEMENT OF REVENUE AND EXPENSES (Continued)

OTATEMENT OF REVENUE AND EXICE COLOR	Jonath	/
	1 Current Year	2 Prior Year
CAPITAL AND SURPLUS ACCOUNT		
Capital and surplus prior reporting year	153,627,228	146,289,952
Net income or (loss) from Line 32		55,351,002
Change in valuation basis of aggregate policy and claim reserves		
Capital Changes:		
14.2 Transferred from surplus (Stock Dividend)	0	0
14.3 Transferred to surplus		
Surplus adjustments:		
45.1 Paid in	0	0
45.2 Transferred to capital (Stock Dividend)		
45.3 Transferred from capital		
Dividends to stockholders	(49,000,000)	(29,200,000
Aggregate write-ins for gains or (losses) in surplus	(1,288,835)	(1,288,835
Net change in capital and surplus (Lines 34 to 47)	(18,769,138)	7,337,276
Capital and surplus end of reporting period (Line 33 plus 48)	134,858,090	153,627,228
DETAILS OF WRITE-INS		
Deferred gain on sale-leaseback transaction	(1,288,835)	(1,288,835
Summary of remaining write-ins for Line 47 from overflow page	0	0
Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above)	(1,288,835)	(1,288,835
	Capital and surplus prior reporting year	CAPITAL AND SURPLUS ACCOUNT Capital and surplus prior reporting year

CASH FLOW

	0,13111 2011		
		1	2
		Current Year	Prior Year
	Cash from Operations		
1.	Premiums collected net of reinsurance	1,230,672,774	1, 191, 208, 729
2.	Net investment income	13,350,807	10,810,794
3.	Miscellaneous income	0	0
4.	Total (Lines 1 through 3)	1,244,023,581	1,202,019,523
5.	Benefit and loss related payments	1, 134, 643, 067	1,056,616,808
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		
7.	Commissions, expenses paid and aggregate write-ins for deductions	73,287,196	188,886,843
8.	Dividends paid to policyholders		
9.	Federal and foreign income taxes paid (recovered) net of \$(2,198,824) tax on capital gains (losses)	6,532,399	22,714,510
10.	Total (Lines 5 through 9)	1,214,462,662	1,268,218,161
11.	Net cash from operations (Line 4 minus Line 10)	29,560,919	(66, 198, 638)
	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid:	470 405 000	04 550 000
	12.1 Bonds		, ,
	12.2 Stocks		
	12.3 Mortgage loans		
	12.4 Real estate		
	12.5 Other invested assets		
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		(6,874)
	12.7 Miscellaneous proceeds	5,222,476	4,189,540
	12.8 Total investment proceeds (Lines 12.1 to 12.7)	181,387,590	65,736,488
13.	Cost of investments acquired (long-term only):		
	13.1 Bonds	94 , 173 , 408	94,150,206
	13.2 Stocks	0	0
	13.3 Mortgage loans	0	0
	13.4 Real estate	0	0
	13.5 Other invested assets	0	0
	13.6 Miscellaneous applications	0	3,699,932
	13.7 Total investments acquired (Lines 13.1 to 13.6)	94,173,408	97,850,138
14.	Net increase/(decrease) in contract loans and premium notes	0	0
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	87,214,182	(32,113,650)
	Cash from Financing and Miscellaneous Sources		
16.	Cash provided (applied):		
	16.1 Surplus notes, capital notes	0	0
	16.2 Capital and paid in surplus, less treasury stock		
	16.3 Borrowed funds		
	16.4 Net deposits on deposit-type contracts and other insurance liabilities		
	16.5 Dividends to stockholders		29,200,000
	16.6 Other cash provided (applied)		126,236,521
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	(123,736,724)	97,036,521
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	(6,961,623)	(1,275,767)
19.	Cash, cash equivalents and short-term investments:		
	19.1 Beginning of year	6,901,785	8,177,552
	19.2 End of year (Line 18 plus Line 19.1)	(59,839)	6,901,785

Note: Supplemental disclosures of cash flow information for non-cash transactions:	

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

					OI OF	EKAIIC		LINLO		OHALO:	J				
		1		hensive	4	5	6	7	8	9	10	11	12	13	14
			(Hospital 8					Fadaral							
			2	3	Medicare			Federal Employees Health	Title XVIII	Title XIX		Disability	Long-Term		Other
		Total	Individual	Group	Supplement	Vision Only	Dental Only	Benefits Plan	Medicare	Medicaid	Credit A&H	Income	Care	Other Health	Non-Health
1.	Net premium income	1,218,705,924	154,465,317	708, 157, 082	55,694,146	5,726,632	10,659,067	276,405,605	19,480					7,578,595	
2.	Change in unearned premium reserves and reserve			, ,	, ,	, ,	, ,	, ,	,						
	for rate credit	31, 171, 052	3,136,681	24, 183, 827	(2,229)		1,723	3,858,321	(7,271)						
3.	Fee-for-service (net of \$														
	medical expenses)	0													XXX
4.	Risk revenue	0													XXX
5.	Aggregate write-ins for other health care related														
	revenues		0	0	0	0	0	0	0	0	0	0	0	0	XXX
6.	Aggregate write-ins for other non-health care related														
_	revenues		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
7.	Total revenues (Lines 1 to 6)	1,249,876,976	157,601,998	732,340,909	55,691,917	5,726,632	10,660,790	280, 263, 926	12,209	0	0	0	0	7,578,595	
8.	Hospital/medical benefits	720,873,672	79,338,081	409,024,915	42,330,003	0.700.440	10,874	178,824,148	(18, 101)					11,363,752	XXX
9.	Other professional services	71,935,978	4,961,457	38,477,974	7,610,957	3,796,443	2,952,114	14, 144, 671	(7,638)						XXX
10.	Outside referrals	12,593,290	796,233	6,866,297		102,350	4,809,550			• • • • • • • • • • • • • • • • • • • •					XXX
11.	Emergency room and out-of-area		8,651,959	69,676,050	1,551,827			60,000,000	(040.704)	• • • • • • • • • • • • • • • • • • • •					XXX
12.	Prescription drugs	213,822,801	25,745,858	121,487,831	(721,227)			68,260,060	(949,721)						XXX
13.	Aggregate write-ins for other hospital and medical	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
14.	Incentive pool, withhold adjustments and bonus	7,091,278	1,239,438	4,767,728				1,084,112							xxx
15.	amounts	1, 106, 196, 855	1,239,436	650,300,795	50.790.420	3.898.793	7,772,538	262,312,991	(975.460)		Λ	0			XXX
16.	Net reinsurance recoveries	(201,649)	(201,763)		30,730,420			202,312,331	(373,400)		0			11,303,732	XXX
17.	Total medical and hospital (Lines 15 minus 16)	1, 106, 398, 504	(201,763)	650,300,795	50.790.420	3.898.793	7.772.538	262,312,991	(975.460)	Λ					XXX
17.	Non-health claims (net)	1, 100, 390, 304	120,934,769	XXX		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
19.	Claims adjustment expenses including						^^^								
19.	\$ 16,800,830 cost containment expenses	33,376,055	6.371.103		3.062.766	265 . 438	657.933	5,343,266	29.469					(440.422)	
20.	General administrative expenses	68,860,662	14.736.045	41.833.182		613.945		12,358,710	68.163					(9.355.175)	
20.	Increase in reserves for accident and health		14,730,043	41,000,102		013,943	1,321,700	12,330,710	00, 103					(9,300,170)	
21.	contracts	0													XXX
22.	Increase in reserves for life contracts		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
23.	Total underwriting deductions (Lines 17 to 22)	1.208.635.221	142.041.937	710.220.479	60,937,212	4.778.176	9.952.237	280.014.967	(877.828)	Λ	0	0	0	1.568.041	0
24.	Net underwriting gain or (loss) (Line 7 minus Line	1,200,000,221	172,071,007					200,014,007	(077,020)					1,000,041	
24.	23)	41,241,755	15,560,061	22.120.430	(5,245,295)	948.456	708.553	248.959	890.037	0	0	0	0	6,010,554	0
	DETAILS OF WRITE-INS	, , , , ,	-,-,	, , ,	(-, -, -,		,	,	, ,					, , , , , , , , , , , , ,	
0501.	22.7.112.00														xxx
0502.															XXX
0503.															XXX
0598.	Summary of remaining write-ins for Line 5 from														
	overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
0599.	Totals (Lines 0501 thru 0503 plus 0598) (Line 5													1	
	above)	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
0601.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0602.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0603.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0698.	Summary of remaining write-ins for Line 6 from														
	overflow page	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
0699.	Totals (Lines 0601 thru 0603 plus 0698) (Line 6														
	above)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
1301.														····	XXX
1302.															XXX
1303.															XXX
1398.	Summary of remaining write-ins for Line 13 from		•							_				1	2007
1	overflow page	0	0	0	0	0	0	0	0	0	0	0	0	J0	XXX
1399.	Totals (Lines 1301 thru 1303 plus 1398) (Line 13	0	^	_	^	_	^	_		0	0	_	0	0	VVV
	above)	0	U	U	U	U	0	U	U	U	0	U	0	1 0	XXX

m

ANNUAL STATEMENT FOR THE YEAR 2023 OF THE Anthem Health Plans of Maine, Inc.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMILIMS

PART 1 - PREMIUMS	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
				,
Comprehensive (hospital and medical) individual	154,465,317			154,465,317
Comprehensive (hospital and medical) group	708, 157, 082			708 , 157 , 082
3. Medicare Supplement	55,694,146			55,694,146
4. Vision only	5,726,632			5,726,632
5. Dental only	10,659,067			10,659,067
6. Federal Employees Health Benefits Plan	276,405,605			276,405,605
7. Title XVIII - Medicare	19,480			19,480
8. Title XIX - Medicaid	0			0
9. Credit A&H				0
10. Disability Income				0
11. Long-Term Care				0
12. Other health	7,612,670		34,075	7,578,595
13. Health subtotal (Lines 1 through 12)	1,218,739,999	0	34,075	1,218,705,924
14. Life	0			0
15. Property/casualty	0			0
16. Totals (Lines 13 to 15)	1,218,739,999	0	34,075	1,218,705,924

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

		1		hensive & Medical)	4	5	6	7	8	9	10	11	12	13	14
		Total	2 Individual	3 Group	Medicare Supplement	Vision Only	Dental Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non-Health
1.	Payments during the year:														
	1.1 Direct	1,129,097,729	119,391,122	683,462,898	47,347,854	4,047,080	7,762,784	260,845,181	(943, 100)					7, 183, 910	
	1.2 Reinsurance assumed	0													
	1.3 Reinsurance ceded	13,550												13,550	
	1.4 Net	1, 129, 084, 179	119,391,122	683,462,898	47,347,854	4,047,080	7,762,784	260,845,181	(943, 100)	0	0	0	0	7,170,360	0
2.	Paid medical incentive pools and bonuses	6,991,530	1,262,683	4,668,608				1,066,784						(6,545)	
3.	Claim liability December 31, current year from Part 2A:														
	3.1 Direct	142,501,268	15,755,144	72,225,685	9,281,284	256,902	604,472		13	0	0	0	0	6,209,202	0
	3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0		0	0	0
	3.3 Reinsurance ceded	12,029	0	0	0	0	0		0	0	0	0	0	12,029	0
	3.4 Net	142,489,239	15,755,144	72,225,685	9,281,284	256,902	604,472	38, 168, 566	13	0	0	0	0	6, 197, 173	0
	Claim reserve December 31, current year from Part 2D: 4.1 Direct	0													
	4.2 Reinsurance assumed	0													
	4.3 Reinsurance ceded	0													
	4.4 Net	0		0	0	n	0	0	0	n	0	0		0	0
	Accrued medical incentive pools and				0		0				0	0		0	0
	bonuses, current year	1,387,425	262,227	897,669				212,838						14,691	
	Net health care receivables (a)	1,432,642	455,995	1,050,600	(264, 136)		1,909	305,209	26,766					(143,701)	
7.	Amounts recoverable from reinsurers December 31, current year	0													
	Claim liability December 31, prior year from Part 2A:	171 000 770	4F 40C C00	100 104 010	C 100 054	405 400	F00, 000	07 470 050	5.607	0	0	0	0	0 170 001	
	8.1 Direct	171,060,778	15,196,683	109, 104, 916	6,102,854	405 , 189	592,809	37,479,659		0	0		0	2,173,061	0
	8.2 Reinsurance assumed	0	0	0	0	0	0			0	0	0	0	0	0
	8.3 Reinsurance ceded	227,228	201,763	0	0	0	0	0	0	0	0	0	0	25,465	0
	8.4 Net	170,833,550	14,994,920	109,104,916	6,102,854	405 , 189	592,809	37,479,659	5,607	0	0	0	0	2,147,596	0
	from Part 2D: 9.1 Direct	^													1
		0											•		·····
	9.2 Reinsurance assumed								·····						·····
	9.4 Net			0	^	^									^
	Accrued medical incentive pools and bonuses, prior year	1.287.677	285.472	798.549	0	U		195,510	0	0	0			8,146	0
11.	Amounts recoverable from reinsurers	, ,	200,472	700,040				100,010						0,140	
	December 31, prior year Incurred Benefits:	0													
	12.1 Direct	1,099,105,577	119,493,588	645,533,067	50,790,420	3,898,793	7,772,538	261,228,879	(975,460)	0	0			11,363,752	0
	12.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0			0	0
	12.3 Reinsurance ceded	(201,649)	(201,763)	0	0	0	0	0	0	0	0	_			0
	12.4 Net	1,099,307,226	119,695,351	645,533,067	50,790,420	3,898,793	7,772,538	261,228,879	(975,460)	0	0	0	0	11,363,638	0
13.	Incurred medical incentive pools and bonuses	7,091,278	1,239,438	4,767,728	0	0	0	1,084,112	0	0	0	0	0	0	0

⁽a) Excludes \$48,129,335 loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY FND OF CURRENT YEAR

					PAR	T 2A - CLAIMS	LIADILII I ENI	OF CURREN	ITEAR						
		1	Compre		4	5	6	7	8	9	10	11	12	13	14
			(Hospital 8	,											
			2	3				Federal							
					Medicare			Employees Health	Title XVIII	Title XIX		Disability	Long-Term		Other
		Total	Individual	Group	Supplement	Vision Only	Dental Only	Benefits Plan	Medicare	Medicaid	Credit A&H	Income	Care	Other Health	Non-Health
	December 1: December 1 Adia december 1					,									
1.	Reported in Process of Adjustment:														
	1.1 Direct	48,600,651	6,558,697	30,213,408	4,875,749	81,239	60,778	6,811,432	0	0	0	0	0	(652)	
	1.2 Reinsurance assumed	0													
	1.3 Reinsurance ceded	0													
	1.4 Net	48,600,651	6,558,697	30,213,408	4,875,749	81,239	60,778	6,811,432	0	0	0	0	0	(652)	0
2.	Incurred but Unreported:														
	2.1 Direct	93,900,617	9, 196, 447	42,012,277	4,405,535	175,663	543,694	31,357,134	13	0	0	0	0	6,209,854	
	2.2 Reinsurance assumed	0													
	2.3 Reinsurance ceded	12,029												12,029	
	2.4 Net	93,888,588	9, 196, 447	42,012,277	4,405,535	175,663	543,694	31,357,134	13	0	0	0	0	6, 197, 825	0
3.	Amounts Withheld from Paid Claims and Capitations:														
	3.1 Direct	0													
	3.2 Reinsurance assumed	0													
	3.3 Reinsurance ceded	0													
	3.4 Net	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.	TOTALS:														
	4.1 Direct	142,501,268	15,755,144	72,225,685	9,281,284	256,902	604,472	38,168,566	13	0	0	0	0	6,209,202	0
	4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4.3 Reinsurance ceded	12,029	0	0	0	0	0	0	0	0	0	0	0	12,029	0
	4.4 Net	142,489,239	15,755,144	72,225,685	9,281,284	256,902	604,472	38,168,566	13	0	0	0	0	6,197,173	0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

	Claims Paid	During the Year	Claim Reserve a	nd Claim Liability	5	6
	1	2	3	4		Estimated Claim Reserve and Claim
Line of Business	On Claims Incurred Prior to January 1 of Current Year	On Claims Incurred During the Year	On Claims Unpaid December 31 of Prior Year	On Claims Incurred During the Year	Claims Incurred In Prior Years (Columns 1 + 3)	Liability December 31 of Prior Year
Comprehensive (hospital and medical) individual	6,772,450	112,618,672	1,273,252	14,481,893	8,045,702	14,994,921
Comprehensive (hospital and medical) group	82,849,491	600,613,407	6,426,888	65,798,799		109, 104, 915
3. Medicare Supplement	5,802,293	41,545,562	34,855	9,246,427	5,837,148	6,102,854
4. Vision Only	264,865	3,782,215	23 , 133	581,338	287,998	405, 189
5. Dental Only	425,928	7,336,856	523	256,379	426,451	592,809
6. Federal Employees Health Benefits Plan	35,178,044	225,667,137	1,663,013			37,479,659
7. Title XVIII - Medicare	(958,445) 15,346	13	0	(958,432)	5,607
8 Title XIX - Medicaid	0	0	0	0	0	0
9. Credit A&H	0	0	0	0	0	0
10. Disability Income	0	0	0	0	0	0
11. Long-Term Care	0	0	0	0	0	0
12. Other health	919,517	6,250,842	2,070,785	4,126,388	2,990,302	2,147,596
13. Health subtotal (Lines 1 to 12)	131,254,143	997,830,037	11,492,462	130,996,777	142,746,605	170,833,550
14. Health care receivables (a)	3,079,080	10,619,158	0	0	3,079,080	12,265,595
15. Other non-health	0	0	0	0	0	0
16. Medical incentive pools and bonus amounts	372,464	6,619,066	127,920	1,259,505	500,384	1,287,677
17. Totals (Lines 13 - 14 + 15 + 16)	128,547,527	993,829,945	11,620,382	132,256,282	140,167,909	159,855,632

⁽a) Excludes \$48, 129,335 loans or advances to providers not yet expensed.

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Comprehensive (Hospital & Medical)

		Cumulative Net Amounts Paid					
		1	2	3	4	5	
	Year in Which Losses Were Incurred	2019	2020	2021	2022	2023	
1.	Prior	49,539	49,527	49,657	50,811	50,811	
2.	2019	652,969	721,237	721,985	722,461	721,250	
3.	2020	XXX	559,762	633,321	635,407	635,956	
4.	2021	XXX	XXX	609,140	710,466	713,052	
5.	2022	XXX	XXX	XXX	649,216	734,452	
6.	2023	XXX	XXX	XXX	XXX	708,780	

Section B - Incurred Health Claims - Comprehensive (Hospital & Medical)

	Sum of Cumulative Net A		Liability, Claim Resetanding at End of Ye		ve Pool and Bonuses
	1	2	3	4	5
Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1. Prior	50,217	49,794	49,894	51,670	50,811
2. 2019	723,846	722,797	722,594	722,791	721,251
3. 2020	XXX	645,015	637,810	636,833	637,221
4. 2021	XXX	XXX	730,308	716,641	714,868
5. 2022	XXX	XXX	XXX	765,610	739 , 192
6. 2023	XXX	XXX	XXX	XXX	790,098

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Comprehensive (Hospital & Medical)

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2019	867,035	721,250	28,235	3.9	749,485	86.4	0	0	749,485	86.4
2.	2020	798,688	635,956	30,883	4.9	666,839	83.5	1,265	0	668, 104	83.7
3.	2021	824,542	713,052	30,961	4.3	744,013	90.2	1,816	70	745,899	90.5
4.	2022	866,646	734,452	27,261	3.7	761,713	87.9	4,740	121	766,574	88.5
5.	2023	889,943	708,780	20,990	3.0	729,770	82.0	81,318	2,178	813,266	91.4

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Medicare Supplement

	Cumulative Net Amounts Paid						
	1	2	3	4	5		
Year in Which Losses Were Incurred	2019	2020	2021	2022	2023		
1. Prior	4,348	5,163	5 , 138	5 , 133	5 , 133		
2 2019		41,343	41,362	41,320	41,307		
3. 2020	XXX	33,581	40,668	40,675	41,002		
4. 2021	XXX	XXX	41,886	47,039	47,087		
5. 2022	XXX	XXX	XXX	42,141	47,533		
6. 2023	XXX	XXX	XXX	XXX	41,093		

Section B - Incurred Health Claims - Medicare Supplement

	Sum of Cumulative Net A	Amount Paid and Claim Outs	n Liability, Claim Rese standing at End of Ye	erve and Medical Incenti ar	ve Pool and Bonuses
	1	2	3	4	5
Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1. Prior	4,724	5,325	5,301	5,133	5,133
2. 2019	43,240	42,182	42,145	41,320	41,307
3. 2020	XXX	41,910	40,680	40,676	41,001
4. 2021	XXX	XXX	46,679	47,045	47,093
5. 2022	XXX	XXX	XXX	48,237	47,563
6. 2023	XXX	XXX	XXX	XXX	50,339

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Medicare Supplement

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2019		41,307	3,461	8.4	44,768	87.9	0	0	44,768	87.9
2.	2020		41,002	3,343	8.2	44,345	78.7	(1)	0	44,344	78.7
3.	2021	58,747	47,087	3,812	8.1	50,899	86.6	6	0	50,905	86.7
4.	2022		47,533	3,647	7.7	51, 180	87.4	30	1	51,211	87.4
5.	2023	55,692	41,093	2,601	6.3	43,694	78.5	9,246	164	53,104	95.4

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Dental Only

		Cumulative Net Amounts Paid							
		1	2	3	4	5			
	Year in Which Losses Were Incurred	2019	2020	2021	2022	2023			
1.	Prior	314		321	321	321			
2.	2019	6,442	6,798	6,807	6,807	6,807			
3.	2020	XXX	5,225	5,724	5,734	5,734			
4.	2021	XXX	XXX	7,015	7,455	7,470			
5.	2022	XXX	XXX	XXX	7,217	7,628			
6.	2023	XXX	XXX	XXX	XXX	7,333			

Section B - Incurred Health Claims - Dental Only

	Total I man in the man							
		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool Outstanding at End of Year						
		1	2	3	4	5		
	Year in Which Losses Were Incurred	2019	2020	2021	2022	2023		
1.	Prior	322	321	321	321	321		
2	. 2019	6,933	6,807	6,808	6,807	6,807		
3	. 2020	XXX	5,788	5,740	5,736	5,734		
4	2021	XXX	XXX	7,653	7,474	7,470		
5	2022	XXX	XXX	XXX	7,789	7,628		
6	2023	XXX	XXX	XXX	XXX	7.589		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Dental Only

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2019	9,161	6,807	687	10.1	7,494	81.8	0	0	7,494	81.8
2.	2020	8.928	5.734	619	10.8	6.353	71.2	0	0	6.353	71.2
3.	2021		7,470		9.9	8.209	75.6	0	0	8.209	75.6
4.	2022		7.626	740	9.7	8.366	77.7	0	0	8.366	77.7
5.	2023	10,661	7,335	579	7.9	7,914	74.2	256	12	8, 182	76.7

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Vision Only

			Cun	nulative Net Amounts F	aid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1.	Prior	244	244	244	244	244
2.	2019	5,527	5,867	5,859	5,858	5,858
3.	2020	XXX	4,666	4,920	4,915	4,915
4.	2021	XXX	XXX	5,446	5,720	5,720
5.	2022	XXX	XXX	XXX	5, 121	5,386
6.	2023	XXX	XXX	XXX	XXX	3,782

Section B - Incurred Health Claims - Vision Only

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Po Outstanding at End of Year						
Year in Which Losses Were Incurred	1 2019	2 2020	3 2021	4 2022	5 2023		
1. Prior	241	244	244	244	244		
2. 2019	5,945	5,867	5,859	5,858	5,858		
3. 2020	XXX	5,130	4,920	4,915	4,915		
4. 2021	XXX	XXX	5,885	5,720	5,722		
5. 2022	XXX	XXX	XXX	5,526	5,407		
6. 2023	XXX	XXX	XXX	XXX	4,363		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Vision Only

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2019	7,893	5,858	447	7.6	6,305	79.9	0	0	6,305	79.9
2.	2020	7,606	4,915		8.0	5,307	69.8	0	0	5,307	69.8
3.	2021	8,078	5,720	510	8.9	6,230	77.1	2	0	6,232	77.1
4.	2022	8.089	5.386	400	7.4	5.786	71.5	21	0	5.807	71.8
5.	2023	5,727	3,782	237	6.3	4,019	70.2	581	6	4,606	80.4

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Federal Employees Health Benefits Plan Premium

		Cumulative Net Amounts Paid						
		1	2	3	4	5		
	Year in Which Losses Were Incurred	2019	2020	2021	2022	2023		
1.	Prior	17,965	17,754	17,922	17,867	17,867		
2.	2019	189,259	208,694	209, 149	209,022	209,576		
3.	2020	XXX	177,987	199,890	200, 126			
4.	2021	XXX	XXX	193,087	230,597	231,073		
5.	2022	XXX	XXX	XXX	197,925	231,525		
6.	2023	XXX	XXX	XXX	XXX	226,606		

Section B - Incurred Health Claims - Federal Employees Health Benefits Plan Premium

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool ar Outstanding at End of Year							
Year in Which Losses Were Incurred	1 2 3 4 2019 2020 2021 2022							
1. Prior			17,960	17,867	<u>2023</u> 17,867			
2. 2019	210,476	208,615	209,272	209,011	209,565			
3. 2020	XXX	203,666	200,433	200, 158	200,524			
4. 2021	XXX	XXX	235,025	231,051	231,518			
5. 2022	XXX	XXX	XXX	235, 125	232,706			
6. 2023	XXX	XXX	XXX	XXX	263,321			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Federal Employees Health Benefits Plan Premium

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2019	223,242	209,576	4,840	2.3	214,416	96.0	(11)	0	214,405	96.0
2.	2020	223,756	200,472	5,200	2.6	205,672	91.9	52	1	205,725	91.9
3.	2021	249,576	231,073	5,503	2.4	236,576	94.8	445	11	237,032	95.0
4.	2022	247.801	231.525	5.261	2.3	236.786	95.6	1.181	28	237.995	96.0
5	2023	280, 264	226, 606	4 490	2.0	231 096	82.5	36 715	857	268 668	95.9

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)
Section A - Paid Health Claims - Title XVIII

	Godien A Tala Health Glande Thie Athir					
			Cumu	lative Net Amounts F	Paid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1.	Prior	(224)	(459)	(473)	(470)	(470)
2.	2019	895	945	946	944	921
3.	2020	XXX	883	1.829	1.690	1.689
4.	2021	XXX	XXX	266	267	(676)
5.	2022	XXX	XXX	XXX	0	8
6.	2023	XXX	XXX	XXX	XXX	(2)

Section B - Incurred Health Claims - Title XVIII

	Sum of Cumulative Net A	mount Paid and Cla O	nim Liability, Claim Rese utstanding at End of Ye	erve and Medical Incenti ar	ve Pool and Bonuses
	1	2	3	4	5
Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1. Prior	(339)	(457)	(473)	(464)	(470)
2. 2019	975	946	944	944	921
3. 2020	XXX	1,908	1,828	1,689	1,689
4. 2021	XXX	XXX	280	267	(676)
5. 2022	XXX	XXX	XXX	0	8
6. 2023	XXX	XXX	XXX	XXX	(2)

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2019	612	921	546	59.3	1,467	239.7	0	0	1,467	239.7
2.	2020	1,170	1,689	153	9.1	1,842	157.4	0	0	1,842	157.4
3.	2021	(34)	(676)	21	(3.1)	(655)	1,926.5	0	0	(655)	1,926.5
4.	2022	(86)	8	(25)	(312.5)	(17)	19.8	0	0	(17)	19.8
5.	2023	12	(2)	14	(700.0)	12	100.0	0	0	12	100.0

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted) Section A - Paid Health Claims - Other

			Cur	mulative Net Amounts F	Paid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1. Prior .		544	545	545	545	545
2. 2019		6,316	6,820	6,821	6,919	6,919
3. 2020		XXX	8,266	9,410	9,889	9,889
4. 2021		XXX	XXX	9,023	11,287	11,595
5. 2022		XXX	XXX	XXX	7, 139	7,757
6. 2023		XXX	XXX	XXX	XXX	6,238

Section B - Incurred Health Claims - Other

	Sum of Cumulative Net	Amount Paid and Claim Outs	Liability, Claim Rese standing at End of Ye	erve and Medical Incenti ar	ve Pool and Bonuses
	1	2	3	4	5
Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1. Prior	484	544	545	545	545
2. 2019	7,780	6,925	6,822	6,919	6,919
3. 2020	XXX	9,736	9,525	10 , 156	9,889
4. 2021	XXX	XXX	11,011	11,471	12,834
5. 2022	XXX	XXX	XXX	8,844	8,590
6. 2023	XXX	XXX	XXX	XXX	10,377

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Other

	Years in which	1	2	3		5 Claim and Claim Adjustment Expense	6	7	8 Unpaid Claims	9 Total Claims and Claims Adjustment	10
	Premiums were Earned and Claims were Incurred	Premiums Earned	Claims Payment	Claim Adjustment Expense Payments	(Col. 3/2) Percent	Payments (Col. 2 + 3)	(Col. 5/1) Percent	Claims Unpaid	Adjustment Expenses	Expense Incurred (Col. 5+7+8)	(Col. 9/1) Percent
-				Expense Fayinents	Felcent	(COI. 2 + 3)	reiceili	Ciairis Oripaid	Lxperises	(COI. 3+1+8)	reiceili
	1. 2019		6,919	548	7.9	7,467	73.5	0	0	7,467	73.5
	2. 2020		9,889	375	3.8	10,264	76.7	0	0	10,264	76.7
	3. 2021		11,595	161	1.4	11,756	80.2	1,239	6	13,001	88.7
	4. 2022		7,757	(278)	(3.6)	7,479	73.1		11	8,323	81.3
	5. 2023	7,578	6,238	(428)	(6.9)	5,810	76.7	4,139	117	10,066	132.8

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Grand Total

			Cur	nulative Net Amounts P	aid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1. Prior		72,730	73,093	73,354	74,451	74,451
2. 2019			991,704	992,929	993,331	992,638
3. 2020		XXX	790,370	895,762	898,436	899,657
4. 2021		xxx	XXX	865,863	1,012,831	1,015,321
5. 2022		xxx	XXX	XXX	908,759	1,034,289
6. 2023		XXX	XXX	XXX	XXX	993,830

Section B - Incurred Health Claims - Grand Total

	Sum of Cumulative Net A	mount Paid and Claim Outs	Liability, Claim Rese tanding at End of Yea	erve and Medical Incenti ar	ve Pool and Bonuses		
	1 2 3 4						
Year in Which Losses Were Incurred	2019	2020	2021	2022	2023		
1. Prior	72,912	73,404	73,792	75,316	74,451		
2. 2019	999 , 195	994 , 139	994,444	993,650	992,628		
3. 2020	XXX	913, 153	900,936	900 , 163	900,973		
4. 2021	XXX	XXX	1,036,841	1,019,669	1,018,829		
5. 2022	XXX	XXX	XXX	1,071,131	1,041,094		
6. 2023	XXX	XXX	XXX	XXX	1,126,085		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2019		992,638	38,764	3.9	1,031,402	88.2	(11)	0	1,031,391	88.2
2.	2020	1,109,881	899,657	40,965	4.6	940,622	84.7	1,316	1	941,939	84.9
3.	2021	1,166,425	1,015,321	41,707	4.1	1,057,028	90.6	3,508	87	1,060,623	90.9
4.	2022	1,202,014	1,034,287	37,006	3.6	1,071,293	89.1	6,805	161	1,078,259	89.7
5.	2023	1,249,877	993,832	28,483	2.9	1,022,315	81.8	132,255	3,334	1,157,904	92.6

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

			PART	2D - AGGREG	SATE RESERVI	FOR ACCIDE	NT AND HEAL	TH CONTRACT	SONLY					
		1	Compreh		4	5	6	7	8	9	10	11	12	13
			(Hospital &	3	Medicare			Federal Employees Health	Title XVIII	Title XIX		Disability	Long-Term	
		Total	Individual	Group	Supplement	Vision Only	Dental Only	Benefits Plan	Medicare	Medicaid	Credit A&H	Income	Care	Other
1.	Unearned premium reserves	2,567	986	(284)	781	(4)	1,088							
2.	Additional policy reserves (a)	0												
3.	Reserve for future contingent benefits	0												
4.	Reserve for rate credits or experience rating refunds													
	(including \$ for investment income)	91,424,931	400,000	39,441,880	2,792			51,580,259						
5.	Aggregate write-ins for other policy reserves	12,900,954	7,728,283	5,087,546	0	0	0	0	85 , 125	0	0	0	0	0
6.	Totals (gross)	104 , 328 , 452	8 , 129 , 269	44,529,142	3,573	(4)	1,088	51,580,259	85 , 125	0	0	0	0	0
7.	Reinsurance ceded	0												
8.	Totals (Net)(Page 3, Line 4)	104 , 328 , 452	8 , 129 , 269	44,529,142	3,573	(4)	1,088	51,580,259	85 , 125	0	0	0	0	0
9.	Present value of amounts not yet due on claims	0												
10.	Reserve for future contingent benefits	0												
11.	Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	0	0	0	0	0
12.	Totals (gross)	0	0	0	0	0	0			0	0	0	0	0
13.	Reinsurance ceded	0												
14.	Totals (Net)(Page 3, Line 7)	0	0	0	0	0	0	0	0	0	0	0	0	0
	DETAILS OF WRITE-INS													
0501.	Risk Adjustment Redetermination	12,900,954	7,728,283	5,087,546					85 , 125					
0502.														
0503.														
0598.	Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0
0599.	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	12,900,954	7,728,283	5,087,546	0	0	0	0		0	0	0	0	0
1101.														
1102.														
1103.														
1198.	Summary of remaining write-ins for Line 11 from overflow page	0		0	0	0	0	0	0	0	0	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	0	0	0	0	0

(a) Includes \$ _____ premium deficiency reserve.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 - ANALYSIS OF EXPENSES

		PART 3 - ANAL Claim Adjustme	/SIS OF EXPENSE	S 3	4	5
		1 Cost Containment Expenses	2 Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
1	Rent (\$ for occupancy of	Expenses	Lxperises	Expenses	Expenses	Total
	own building)	178 113	310 020	117 280		614 422
2.	Salary, wages and other benefits					
3.	Commissions (less \$					
3.	ceded plus \$ assumed)			12 015 722		12 015 722
4	Legal fees and expenses			, ,		, , ,
4.	Certifications and accreditation fees					
5.	Auditing, actuarial and other consulting services					
6.	Traveling expenses					
7.	- '			1,611,979		
8.	Marketing and advertising					
9.	Postage, express and telephone		·			
10.	Printing and office supplies					
11.	Occupancy, depreciation and amortization					
12.	Equipment	228	1,070	165,459		166,757
13.	Cost or depreciation of EDP equipment and software	(169,312)	150,683	6,203,502		6, 184,873
14.	Outsourced services including EDP claims and					
	other services					
15.	Boards, bureaus and association fees	3,668	163	308,545		312,376
16.	Insurance, except on real estate			262,250		262,250
17.	Collection and bank service charges	500		689,505		690,005
18.	Group service and administration fees	474	1,372,732	8,646,326		10,019,532
19.	Reimbursements by uninsured plans			(41, 162, 225)		(41, 162, 225
20.	Reimbursements from fiscal intermediaries					(
21.	Real estate expenses	14	66	791,192		791,272
22.	Real estate taxes			3,628		3,628
23.	Taxes, licenses and fees:					
	23.1 State and local insurance taxes	(267,509)	(167,214)	5,888,956		5,454,233
	23.2 State premium taxes			9,489,644		9,489,644
	23.3 Regulatory authority licenses and fees	22,210	8,995	142,255		173,460
	23.4 Payroll taxes	792,233	651,019	1,656,927		3, 100, 179
	23.5 Other (excluding federal income and real estate taxes)			5,263,898		5,263,898
24.	Investment expenses not included elsewhere				424,097	424,097
25.	Aggregate write-ins for expenses	784,089	3,298,732	5,572,510	0	9,655,33
26.	Total expenses incurred (Lines 1 to 25)	16,800,830	16,575,225	68,860,662	424,097	(a) 102,660,814
27.	Less expenses unpaid December 31, current year		3,583,051	17,053,266		20,636,317
28.	Add expenses unpaid December 31, prior year	0	3,566,155	15,461,209	0	19,027,364
29.	Amounts receivable relating to uninsured plans, prior year			148,984,274		148,984,274
30.	Amounts receivable relating to uninsured plans, current year			81,648,929		81,648,929
31.	Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	16,800,830	16,558,329	(66,740)	424,097	33,716,516
	DETAILS OF WRITE-INS					
2501.	Miscellaneous expense	784,089	3,298,732	5,572,510		9,655,331
2502.						
2503.						
2598.	Summary of remaining write-ins for Line 25 from overflow page	0	0	0	0	
	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above) des management fees of \$	784,089	3,298,732	5,572,510 n-affiliates.	0	9,655,331

EXHIBIT OF NET INVESTMENT INCOME

		1	2
L		Collected During Year	Earned During Year
1.	U.S. government bonds	(a)330,297	222,055
1.1	Bonds exempt from U.S. tax	(a)	
1.2	Other bonds (unaffiliated)	(a)12,954,176	12,361,366
1.3	Bonds of affiliates		0
2.1	Preferred stocks (unaffiliated)		0
2.11	Preferred stocks of affiliates	(- /	0
2.2	Common stocks (unaffiliated)		0
2.21	Common stocks of affiliates	0	0
3.	Mortgage loans	(c)0	0
4.	Real estate		0
5	Contract Loans	0	0
6	Cash, cash equivalents and short-term investments	(e)547,704	547,704
7	Derivative instruments	(f)0	0
8.	Other invested assets		0
9.	Aggregate write-ins for investment income	69,200	72,955
10.	Total gross investment income	13,901,378	13,204,081
11.	Investment expenses		
12.	Investment taxes, licenses and fees, excluding federal income taxes		(g)0
13.	Interest expense		(h)
14.	Depreciation on real estate and other invested assets		(i)
15.	Aggregate write-ins for deductions from investment income		0
16.	Total deductions (Lines 11 through 15)		424,097
17.	Net investment income (Line 10 minus Line 16)		12,779,984
	DETAILS OF WRITE-INS		
0901.	Miscellaneous income	32,602	32,602
0902.	Securities lending	36,598	40,353
0903.			
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	69,200	72,955
1501.			
1502.			
1503.			
1598.	Summary of remaining write-ins for Line 15 from overflow page		0
1599.	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)		0

(a) Includes \$	938,208	accrual of discount less \$	823,710	amortization of premium and less	\$200,564	paid for accrued interest on purchases.
(b) Includes \$	0	accrual of discount less \$	0	amortization of premium and less	\$0	paid for accrued dividends on purchases
(c) Includes \$	0	accrual of discount less \$	0	amortization of premium and less	\$	paid for accrued interest on purchases.
(d) Includes \$		for company's occupancy	of its own building	s; and excludes \$	interest on encu	mbrances.
(e) Includes \$	95,224	accrual of discount less \$	0	amortization of premium and less	\$0	paid for accrued interest on purchases.
(f) Includes \$	0	accrual of discount less \$	0	amortization of premium.		
	and Separate Acco		\$	investment taxes, licenses and	fees, excluding fede	eral income taxes, attributable to
(h) Includes \$		interest on surplus notes a	ınd \$	interest on capital notes.		
(i) Includes \$	0	depreciation on real estate	e and \$	depreciation on other inve	ested assets	

EXHIBIT OF CAPITAL GAINS (LOSSES)

						_
		1	2	3	4	5
				Total Realized Capital	Change in	Change in Unrealized
		Realized Gain (Loss)	Other Realized	Gain (Loss)	Unrealized Capital	Foreign Exchange
		On Sales or Maturity	Adjustments	(Columns 1 + 2)	Gain (Loss)	Capital Gain (Loss)
1.	U.S. Government bonds					
1.1	Bonds exempt from U.S. tax			0,270,200)	······································	
1.2	Other bonds (unaffiliated)	(4 404 651)	Λ	(4 404 651)	(154 040)	0
1.3						0
_	Bonds of affiliates	0				0
2.1	Preferred stocks (unaffiliated)				0	0
2.11	Preferred stocks of affiliates				0	0
2.2	Common stocks (unaffiliated)	0	0	0	0	0
2.21	Common stocks of affiliates			0	0	0
3.	Mortgage loans		0	0	0	0
4.	Real estate			0		0
5.	Contract loans	0	0	0		
6.	Cash, cash equivalents and short-term investments			(175)	0	
7.	Derivative instruments	0	0	0	0	
8.	Other invested assets				0	0
9.	Aggregate write-ins for capital gains (losses)	1,288,835	0	1,288,835	0	0
10.	Total capital gains (losses)	(9,386,290)	0		(154,040)	0
	DETAILS OF WRITE-INS					
0901.	Deferred gain on sale-leaseback transaction	1 288 835		1 288 835		
0902.	zoromou gum on ouro roudozuon trunouetron mm					
0903.						
0903.	Summary of remaining write-ins for Line 9 from					
0990.	overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9,	0	0		0	
0999.	above)	1,288,835	0	1,288,835	0	0
		.,,		.,,		l

EXHIBIT OF NON-ADMITTED ASSETS

		Current Year Total	2 Prior Year Total Nonadmitted Assets	Change in Total Nonadmitted Assets
	Bonds (Schedule D)	Nonadmitted Assets	Nonadmitted Assets	(Col. 2 - Col. 1)
1. 2.	Stocks (Schedule D):			
۷.	2.1 Preferred stocks			0
0	2.2 Common stocks			0
3.	Mortgage loans on real estate (Schedule B):			0
	3.1 First liens			
	3.2 Other than first liens			0
4.	Real estate (Schedule A):			0
	4.1 Properties occupied by the company			
	4.2 Properties held for the production of income			
_	4.3 Properties held for sale			0
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)			
6.	Contract loans			
7.	Derivatives (Schedule DB)			0
8.	Other invested assets (Schedule BA)			
9.	Receivables for securities			
10.	Securities lending reinvested collateral assets (Schedule DL)			
11.	Aggregate write-ins for invested assets			
12.	Subtotals, cash and invested assets (Lines 1 to 11)	0	0	0
13.	Title plants (for Title insurers only)			0
14.	Investment income due and accrued			0
15.	Premiums and considerations:			
	15.1 Uncollected premiums and agents' balances in the course of collection	859,557	1,498,849	639,292
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due			0
	15.3 Accrued retrospective premiums and contracts subject to redetermination			0
16.	Reinsurance:			
	16.1 Amounts recoverable from reinsurers			0
	16.2 Funds held by or deposited with reinsured companies			0
	16.3 Other amounts receivable under reinsurance contracts			0
17.	Amounts receivable relating to uninsured plans	24,451,824	27,538,625	3,086,801
18.1	Current federal and foreign income tax recoverable and interest thereon			0
	Net deferred tax asset			0
19.	Guaranty funds receivable or on deposit			0
20.	Electronic data processing equipment and software			0
21.	Furniture and equipment, including health care delivery assets	393, 181	406,005	12,824
22.	Net adjustment in assets and liabilities due to foreign exchange rates			0
23.	Receivable from parent, subsidiaries and affiliates			
24.	Health care and other amounts receivable			
25.	Aggregate write-ins for other than invested assets	2,033,105	1,908,535	(124,570
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)			
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts			0
28.	Total (Lines 26 and 27)	50,669,628	50,576,611	(93,017
	DETAILS OF WRITE-INS			
1101.				
1102.				
1103.				
1198.	Summary of remaining write-ins for Line 11 from overflow page		0	
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0
2501.	Prepaid expenses			_
2501. 2502.	Miscellaneous receivables			
	MISCETTANEOUS FECETVADIES	,		•
2503. 2598.				
	Summary of remaining write-ins for Line 25 from overflow page	. 0	0	0

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

			Total Members at End of			6
Source of Enrollment	1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	Current Year Member Months
Health Maintenance Organizations	31,522	29,510	28,616	28,260	28,011	345,629
Provider Service Organizations						
Preferred Provider Organizations	250,281	216,268	216,742	199,300	199,044	2,493,313
4. Point of Service	44,076	43,645	43,428	43,040	42,994	520,149
5. Indemnity Only	23,257	22,670	22,594	22,549	22,372	271,374
Aggregate write-ins for other lines of business	20,758	17,935	18,109	18,413	18,072	217,533
7. Total	369,894	330,028	329,489	311,562	310,493	3,847,998
DETAILS OF WRITE-INS						
0601. Consumer Driven Health Products	20,067	17,029	17,142	17,391	17,010	205,695
0602. Disability and Accident	691	906	967	1,022	1,062	11,838
0603.						
0698. Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0
0699. Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	20,758		18,109	18,413	18,072	217,533

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The accompanying financial statements of Anthem Health Plans of Maine, Inc. (the "Company") have been prepared in conformity with the National Association of Insurance Commissioners' ("NAIC") *Annual Statement Instructions* and in accordance with accounting practices prescribed by the NAIC *Accounting Practices and Procedures Manual* ("NAIC SAP"), subject to any deviations prescribed or permitted by the Maine Bureau of Insurance ("Bureau").

A reconciliation of the Company's net income (loss) and capital and surplus between NAIC SAP and practices prescribed and permitted by the Bureau is shown below:

		SSAP#	F/S Page	F/S Line #	2023	2022
Net	<u>Income</u>					
(1)	Anthem Health Plans of Maine, Inc. state basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	XXX	\$ 33,823,861	\$ 55,351,002
(2)	State Prescribed Practices that is an increase/(decrease) from NAIC SAP:					
(3)	State Permitted Practices that is an increase/(decrease) from NAIC SAP:					
(4)	NAIC SAP (1-2-3=4)	XXX	XXX	XXX	\$ 33,823,861	\$ 55,351,002
Sur	<u>plus</u>					
(5)	Anthem Health Plans of Maine, Inc. state basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	\$134,858,090	\$153,627,228
(6)	State Prescribed Practices that is an increase/(decrease) from NAIC SAP:					
(7)	State Permitted Practices that is an increase/(decrease) from NAIC SAP:				. <u>—</u>	
(8)	NAIC SAP (5-6-7=8)	XXX	XXX	XXX	\$134,858,090	\$153,627,228

B. Use of Estimates in the Preparation of the Financial Statements

Preparation of financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

C. Accounting Policies

Health premiums are earned over the term of the related insurance policies and reinsurance contracts. Premiums written are reported net of excess loss reinsurance ceded and experience rating refunds. Unearned premium reserves are established to cover the unexpired portion of premiums written and are computed by pro rata methods for direct business and based on reports received from ceding companies for reinsurance. Premiums paid by subscribers prior to the effective date are recorded on the balance sheet as premiums received in advance and are subsequently credited to income as earned during the coverage period. Premium rates for certain lines of business are subject to approval by the Bureau. Expenses incurred in connection with acquiring new insurance business, including acquisition costs such as sales commissions, are charged to operations as incurred. All other costs, including underwriting expenses, are charged to operations as incurred.

The Company provides administrative services to various customers on an uninsured basis. Under these arrangements, the customer retains the risk of funding payments for health benefits provided, and the Company may be subject to credit risk of the customer from the time of the Company's claim payment until the Company receives the claim reimbursement. In accordance with SSAP No. 47, *Uninsured Plans*, these claims payments and subsequent reimbursements are excluded from the Company's statutory statement of revenue and expenses. Administrative fees for administering these arrangements are recognized as administrative services are performed and recorded as a reduction to operating expenses.

In addition, the Company uses the following accounting policies:

- (1) Short-term investments include investments with maturities of less than one year and more than three months at the date of acquisition and are reported at amortized cost, which approximates fair value. Non-investment grade short-term investments are stated at the lower of amortized cost or fair value.
- (2) Investment grade bonds not backed by other loans are stated at amortized cost, with amortization calculated based on the modified scientific method, using lower of yield to call or yield to maturity. Non-investment grade bonds are stated at the lower of amortized cost or fair value as determined by various third-party pricing sources.
- (3) The Company has no investments in common stocks of unaffiliated companies.
- (4) The Company has no investments in preferred stocks.
- (5) The Company has no mortgage loans real estate.
- (6) Loan-backed securities are stated at amortized cost. Prepayment assumptions for loan-backed securities and structured securities were obtained from broker-dealer survey values or internal estimates. These assumptions are consistent with the current interest rate and economic environment. The retrospective adjustment method is used to value all loan-backed securities. Non-investment grade loan-backed securities are stated at the lower of amortized cost or fair value.
- (7) The Company has no investments in subsidiaries, controlled and affiliated companies.
- (8) The Company has no investments in joint ventures, partnerships or limited liability companies.
- (9) The Company has no derivative instruments.
- (10) The Company recognizes losses from other-than-temporary impairments ("OTTI") of investments in accordance with Statements of Standard Accounting Practice ("SSAP") No. 26R, *Bonds*; and SSAP No. 30, *Common Stock*; and SSAP No. 32R, *Preferred Stock*.
- (11) The Company does not anticipate investment income as a factor in premium deficiency calculations.
- (12) Unpaid claims and claims adjustment expenses include management's best estimate of amounts based on historical claim development patterns and certain individual case estimates. The established liability considers health benefit provisions, business practices, economic conditions and other factors that may materially affect the cost, frequency and severity of claims. Liabilities for unpaid claims and claim adjustment expenses are based on assumptions and estimates, and while management believes such estimates are reasonable, the ultimate liability may be in excess of or less than the amount provided. The methods for making such estimates and for establishing the resulting liabilities are continually reviewed and changes in estimates are incorporated into current period estimates.
- (13) The Company has not modified its capitalization policy from the prior period.
- (14) Pharmacy rebate receivables are recorded when earned based upon actual rebate receivables billed and an estimate of receivables based upon current utilization of specific pharmaceuticals and provider contract terms.
- (15) Service fees earned from providing administrative services to self-insured customers are deducted from operating expenses, and related claim payments and subsequent reimbursements of those claim payments are excluded from net income.
- (16) The Company sells policies where premiums vary based on loss experience or premium stabilization programs. Retrospectively rated refunds include minimum medical loss ratio ("MLR") rebates per the Affordable Care Act ("ACA"). Risk

adjustment programs transfer premiums from insurers that enroll members with relatively lower health risks to insurers that enroll members with relatively higher health risks. Reserves for rate credits, risk adjustment programs or policy rating refunds are reported in aggregate policy reserves. Accrued retrospective premiums are reported in premiums receivable.

- (17) Premium under the Federal Employee Program ("FEP") is earned when chargeable benefit costs, allowable expenses and retentions are incurred. Deferred premiums are recorded to offset the FEP liabilities for incurred claims but not reported and claims adjustment expenses that are due from the Office of Personnel Management ("OPM") when the claims are ultimately paid.
- (18) A discount rate is applied to guaranty fund liabilities and assets related to assessments from insolvencies of entities that wrote long-term care contracts.

D. Going Concern

Not applicable.

2. Accounting Changes and Corrections of Errors

There were no accounting changes or corrections of errors during the years ended December 31, 2023 and 2022.

3. Business Combinations and Goodwill

A. Statutory Purchase Method

Not applicable.

B. Statutory Merger

Not applicable.

C. Assumption Reinsurance

Not applicable.

D. Impairment Loss

Not applicable.

E. Subcomponents and Calculation of Adjusted Surplus and Total Admitted Goodwill

Not applicable.

4. Discontinued Operations

The Company had no operations that were discontinued during 2023 or 2022.

5. Investments

A. Mortgage Loans, including Mezzanine Real Estate Loans

The Company did not have investments in mortgage loans at December 31, 2023 or 2022.

B. Debt Restructuring

The Company did not have invested assets that were restructured debt at December 31, 2023 or 2022.

C. Reverse Mortgages

The Company did not have investments in reverse mortgages at December 31, 2023 or 2022.

D. Loan-Backed Securities

- (1) Prepayment assumptions for single-class and multi-class mortgage-backed and asset-backed securities were obtained from broker-dealer survey values or internal estimates. The Company used various third-party pricing sources in determining the market value of its loan-backed securities.
- (2) The Company did not recognize OTTI on its loan-backed securities during the year ended December 31, 2023.
- (3) The Company did not hold OTTI on its loan-backed securities at December 31, 2023.
- (4) All impaired securities (fair value is less than cost or amortized cost) for which an other-than-temporary impairment has not been recognized in earnings as a realized loss (including securities with a recognized other-than-temporary impairment for non-interest related declines when a non-recognized interest related impairment remains):
 - a. The aggregate amount of unrealized losses:

		1.	Less than 12 Months	\$ (795,263)
		2.	12 Months or Longer	\$ (6,595,967)
b.	The aggregate related fair value of securities with unrealized losses:			
		1.	Less than 12 Months	\$ 53,298,670
		2.	12 Months or Longer	\$ 73,266,080

(5) The Company's bond portfolio is sensitive to interest rate fluctuations, which impact the fair value of individual securities. Unrealized losses on bonds were primarily caused by the effects of the interest rate environment and the widening of credit spreads on certain securities. The Company currently has the ability and intent to hold these securities until their full cost can be recovered. Therefore, the Company does not believe the unrealized losses represent an OTTI at December 31, 2023 or 2022.

E. Dollar Repurchase Agreements and/or Securities Lending Transactions

- (1) The Company did not enter into repurchase agreements at December 31, 2023 or 2022.
- (2) The Company participates in a securities lending program whereby marketable securities in its investment portfolio are transferred to independent brokers or dealers based on, among other things, their creditworthiness in exchange for collateral initially equal to at least 102% of the market value of the loaned securities. The Company receives the collateral in cash or securities, and if cash is received the cash collateral is thereafter invested according to guidelines of the Company's Investment Policy.

(3) Collateral Received

a. Aggregate amount collateral received

		<u>Fair Value</u>
1. Se	curities Lending	
(a)	Open	\$ 10,449,748
(b)	30 days or less	
(c)	31 to 60 days	_
(d)	61 to 90 days	_
(e)	Greater than 90 days	 <u> </u>
(f)	Sub-total	\$ 10,449,748
(g)	Securities received	1,161
(h)	Total collateral received	\$ 10,450,909

- 2. Dollar repurchase agreement Not applicable.
- b. The fair value of that collateral and of the portion of that collateral that it has sold or repledged \$\\$10,450,909\$
- c. The Company receives cash collateral in an amount in excess of fair value of the securities lent. The Company reinvests the cash collateral according to guidelines of the Company's Investment Policy.
- (4) The Company does not have any securities lending transactions administered by an affiliated agent.

(5) Collateral Reinvestment

a. Aggregate amount collateral reinvested

			<u>Am</u>	ortized Cost	Fair Value
1.	Secu	rities Lending			
	(a)	Open	\$	_	\$ _
	(b)	30 days or less		4,266,502	4,267,866
	(c)	31 to 60 days		2,353,707	2,355,961
	(d)	61 to 90 days		822,877	826,292
	(e)	91 to 120 days		895,293	896,034
	(f)	121 to 180 days		1,407,777	1,408,319
	(g)	181 to 365 days		694,649	695,276
	(h)	1 to 2 years		_	_
	(i)	2 to 3 years		_	_
	(j)	Greater than 3 years			
	(k)	Sub-total	\$	10,440,805	\$ 10,449,748
	(1)	Securities received		1,161	1,161
	(m)	Total collateral reinvested	\$	10,441,966	\$ 10,450,909

- 2. Dollar repurchase agreement Not applicable.
- b. Not applicable.
- (6) Not applicable.
- (7) Not applicable.

F. Repurchase Agreements Transactions Accounted for as Secured Borrowing

The Company did not enter into repurchase agreement transactions accounted for as secured borrowing at December 31, 2023 or 2022.

G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing

(1) The Company accepts repurchase agreements as collateral within its securities lending program.

(2) Type of Repo Trades Used

a. b.

	FIRST QUARTER	SECOND QUARTER	THIRD QUARTER	FOURTH QUARTER
Bilateral (YES/NO)	NO	NO	NO	NO
Tri-Party (YES/NO)	NO	NO	NO	NO

(3) Original (Flow) & Residual Maturity

	FIRST QUARTER	SECOND QUARTER	THIRD QUARTER	FOURTH QUARTER
a. Maximum Amount				
1. Open - No Maturity	\$ —	\$ —	\$ —	\$
2. Overnight	\$ 18,100,000	\$ 18,300,000	\$ 5,737,500	\$ 3,900,000
3. 2 Days to 1 Week	\$ —	\$ —	\$ —	\$ —
4. >1 Week to 1 Month	\$ —	\$ —	\$ —	\$ —
5. >1 Month to 3 Months	\$ —	\$ —	\$ —	\$ —
6. >3 Months to 1 Year	\$ —	\$ —	\$ —	\$ —
7. >1 Year	\$ —	\$ —	\$ —	\$ —
	FIRST QUARTER	SECOND QUARTER	THIRD QUARTER	FOURTH QUARTER
b. Ending Balance			111111	10011111
b. Ending Balance1. Open - No Maturity			111111	10011111
•	QUARTER	QUARTER	QUARTER	QUARTER
1. Open - No Maturity	QUARTER \$ —	QUARTER \$ —	QUARTER	QUARTER \$ —
 Open - No Maturity Overnight 	\$ \$	\$ —	\$ —	\$ — \$ —
 Open - No Maturity Overnight 2 Days to 1 Week 	\$ — \$ — \$ —	\$ — \$ — \$ —	\$ — \$ — \$ —	\$ — \$ — \$ —
 Open - No Maturity Overnight 2 Days to 1 Week >1 Week to 1 Month 	\$ — \$ — \$ — \$ —	\$ — \$ — \$ — \$ —	\$ — \$ — \$ —	\$ — \$ — \$ — \$ —
 Open - No Maturity Overnight 2 Days to 1 Week >1 Week to 1 Month >1 Month to 3 Months 	\$ — \$ — \$ — \$ — \$ —	\$ — \$ — \$ — \$ — \$ — \$ — \$ — \$ — \$ — \$ —	\$ — \$ — \$ — \$ — \$ — \$ — \$ — \$ — \$ — \$ —	\$ — \$ — \$ — \$ — \$ —

(4) Aggregate Narrative Disclosure of Fair Value of Securities Sold and/or Acquired That Resulted in Default

Not applicable.

(5) Fair Value of Securities Acquired Under Repo-Secured Borrowing

	(FIRST QUARTER	SECOND QUARTER		
a. Maximum Amount	\$	18,524,023	\$ 18,769,732	\$ 5,866,992	\$ 3,961,854
b. Ending Balance	\$	_	\$ _	\$ 	\$ _

(6) Securities Acquired Under Repo - Secured Borrowing by NAIC Designation

ENDING BALANCE

	NONE	NAIC 1	NAIC 2	NAIC 3
a. Bonds - FV	\$ _	\$ _	\$ _	\$ _
b. LB & SS - FV	\$ _	\$ _	\$ _	\$ _
c. Preferred Stock - FV	\$ _	\$ 	\$ _	\$
d. Common Stock	\$ _	\$ _	\$ _	\$ _
e. Mortgage Loans - FV	\$ _	\$ 	\$ _	\$
f. Real Estate - FV	\$ _	\$ 	\$ _	\$
g. Derivatives - FV	\$ _	\$ 	\$ _	\$
h. Other Invested Assets - FV	\$ 	\$ 	\$ 	\$
i. Total Assets - FV (Sum of a through h)	\$ 	\$ 	\$ 	\$

ENDING BALANCE

	5 NAIC 4	6 NAIC 5	7 NAIC 6	8 DOES NOT QUALIFY AS ADMITTED
a. Bonds - FV	\$ —	\$ —	\$ —	\$
b. LB & SS - FV	\$ —	\$ —	\$ —	\$
c. Preferred Stock - FV	\$ —	\$ —	\$ —	\$
d. Common Stock	\$ —	\$ —	\$ —	\$
e. Mortgage Loans - FV	\$ —	\$ —	\$ —	\$
f. Real Estate - FV	\$ —	\$ —	\$ —	\$
g. Derivatives - FV	\$ —	\$ —	\$ —	\$
h. Other Invested Assets - FV	\$ —	\$ —	\$ —	\$
i. Total Assets - FV (Sum of a through h)	\$	\$ —	\$ —	\$

(7) Collateral Pledged - Secured Borrowing

	Ç	FIRST QUARTER	SECOND UARTER	Q	THIRD UARTER	OURTH UARTER
a. Maximum Amount						
1. Cash	\$	18,100,000	\$ 18,300,000	\$	5,737,500	\$ 3,900,000
2. Securities (FV)	\$	_	\$ _	\$	_	\$
3. Securities (BACV)		XXX	XXX		XXX	XXX
4. Nonadmitted Subset (BACV)		XXX	XXX		XXX	XXX
b. Ending Balance						
1. Cash	\$	_	\$ _	\$	_	\$
2. Securities (FV)	\$	_	\$ _	\$	_	\$
3. Securities (BACV)	\$	_	\$ _	\$	_	\$
4. Nonadmitted Subset (BACV)	\$	_	\$ _	\$	_	\$

(8) Allocation of Aggregate Collateral Pledged by Remaining Contractual Maturity

	AMOR	TIZED COST	FAIR VALUE
a. Overnight and Continuous	\$		\$ _
b. 30 Days or Less	\$		\$ _
c. 31 to 90 Days	\$		\$ _
d. >90 Days	\$	_	\$ _

(9) Recognized Receivable for Return of Collateral - Secured Borrowing

	FIRST QUARTER	SECOND QUARTER	THIRD QUARTER	FOURTH QUARTER
a. Maximum Amount				_
1. Cash	\$	\$ —	\$ —	\$
2. Securities (FV)	\$ —	\$ —	\$ —	\$
b. Ending Balance				
1. Cash	\$	\$ —	\$ —	\$
2. Securities (FV)	\$	\$ —	\$	\$

(10) Recognized Liability to Return Collateral - Secured Borrowing (Total)

	FIRST QUARTER	SECOND QUARTER	THIRD QUARTER	FOURTH QUARTER
a. Maximum Amount				
 Repo Securities Sold/Acquired with Cash Collateral 	\$ —	\$ —	\$ —	\$ —
2. Repo Securities Sold/Acquired with Securities Collateral (FV)	\$ —	\$ —	\$ —	\$
b. Ending Balance				
 Repo Securities Sold/Acquired with Cash Collateral 	\$ —	\$ —	\$ —	\$ —
2. Repo Securities Sold/Acquired with Securities Collateral (FV)	\$ —	\$	\$	\$

H. Repurchase Agreements Transactions Accounted for as a Sale

The Company did not enter into repurchase agreement transactions accounted for as a sale at December 31, 2023 or 2022.

I. Reverse Repurchase Agreements Transactions Accounted for as a Sale

The Company did not enter into reverse repurchase agreement transactions accounted for as a sale at December 31, 2023 or 2022.

J. Real Estate

- (1) At December 31, 2023 and December 31, 2022, the Company recognized an impairment loss on its investment in real estate of \$2,385 and \$22,149, respectively.
- (2) On July 30, 2015, the Company sold its real estate investment in its office building located at 2 Gannett Drive in South Portland, Maine to WPME001, LLC, a Maine limited liability company, for \$25,800,000. Concurrently, the Company leased back the 2 Gannett Drive in South Portland, Maine office building under a 12 year year lease agreement with four optional 5-year renewal periods. In accordance with statutory accounting principles, the Company accounted for the transaction as a sale-leaseback settled entirely in cash, and recognized the entire gain directly to special surplus funds. The recognized gain to special surplus funds of \$15,466,022 is being amortized to unassigned surplus on a straight-line basis over the 12 year life of the lease. This amount will be reported as a realized capital gain in each year in the statement of revenue and expenses. The amount of realized gain in the statement of revenue and expenses recognized was \$1,288,835 and \$1,288,835 in 2023 and 2022, respectively.
- (3) Not applicable.
- (4) The Company did not engage in retail land sales operations during 2023 or 2022.
- (5) Not applicable.

K. Investments in Low-Income Housing Tax Credits

The Company did not invest in properties generating low-income housing tax credits during 2023 or 2022.

L. Restricted Assets

(1) Restricted assets (including pledged)

		1	2	3	4	5	6	7
Re	stricted Asset Category	Total Gross (Admitted & Nonadmitted) Restricted from Current Year	Total Gross (Admitted & Nonadmitted) Restricted from Prior Year	Increase/ (Decrease) (1 minus 2)	Total Current Year Nonadmitted Restricted	Total Current Year Admitted Restricted (1 minus 4)	Gross Admitted and Nonadmitted Restricted to Total Assets (a)	Admitted Restricted to Total Admitted Assets (b)
a.	Subject to contractual obligation for which liability is not shown	s —	s —	s —	s —	s —	0.00 %	0.00 %
b.	Collateral held under security lending agreements	10,441,966	15,664,442	(5,222,476)	_	\$10,441,966	1.76 %	1.92 %
c.	Subject to repurchase agreements	_	_	_	_	\$ —	0.00 %	0.00 %
d.	Subject to reverse repurchase agreements	_	_	_	_	\$ —	0.00 %	0.00 %
e.	Subject to dollar repurchase agreements	_	_	_	_	\$ —	0.00 %	0.00 %
f.	Subject to dollar reverse repurchase agreements	_	_	_	_	s —	0.00 %	0.00 %
g.	Placed under option contracts	_	_	_	_	s —	0.00 %	0.00 %
h.	Letter stock or securities restricted as to sale-excluding FHLB capital stock	_	_	_	_	s —	0.00 %	0.00 %
i.	FHLB capital stock	_	_	_	_	s —	0.00 %	0.00 %
j.	On deposit with states	809,417	830,197	(20,780)	_	\$ 809,417	0.14 %	0.15 %
k.	On deposit with other regulatory bodies	_	_	_	_	\$ —	0.00 %	0.00 %
1.	Pledged as collateral to FHLB (including assets backing funding agreements)	_	_	_	_	\$ —	0.00 %	0.00 %
m.	Pledged as collateral not captured in other categories	_	_	_	_	s —	0.00 %	0.00 %
n.	Other restricted assets	_	_	_	_	\$ —	0.00 %	0.00 %
0.	Total Restricted Assets	\$ 11,251,383	\$ 16,494,639	\$(5,243,256)	s —	\$11,251,383	1.89 %	2.07 %

⁽a) Column 1 divided by Asset Page, Column 1, Line 28

⁽b) Column 5 divided by Asset Page, Column 3, Line 28

⁽²⁾ Not applicable.

⁽³⁾ Not applicable.

(4) Collateral Received and Reflected as Assets Within the Reporting Entity's Financial Statements

		1	2	3	4
	Collateral Assets	Book/ Adjusted Carrying Value (BACV)	Fair Value	% of BACV to Total Assets (Admitted and Nonadmitted*)	% of BACV to Total Admitted Assets **
a.	Cash	\$ —	\$ —	— %	— %
b.	Schedule D, Part 1	_	_	_	_
c.	Schedule D, Part 2 Section 1	_	_	_	_
d.	Schedule D, Part 2 Section 2	_	_	_	_
e.	Schedule B	_	_	_	_
f.	Schedule A	_	_	_	_
g.	Schedule BA, Part 1	_	_	_	_
h.	Schedule DL, Part 1	10,441,966	10,450,909	1.76	1.92
i.	Other		<u> </u>		
j.	Total Collateral Assets (a+b+c+d+e+f+g+h+i)	\$ 10,441,966	\$ 10,450,909	1.76 %	1.92 %

^{*} Column 1 divided by Asset Page, Line 26 (Column 1)

^{**} Column 1 divided by Asset Page, Line 26 (Column 3)

		<u>1</u>	<u>2</u>
			% of Liability
		Amount	to Total Liabilities *
k.	Recognized Obligation to Return Collateral Asset	\$ 10,441,966	2.55 %

^{*} Column 1 divided by Liability Page, Line 24 (Column 3)

M. Working Capital Finance Investments

The Company did not have any working capital finance investments at December 31, 2023 and 2022.

N. Offsetting and Netting of Assets and Liabilities

The Company did not have any offsetting or netting of assets and liabilities at December 31, 2023 and 2022.

O. 5GI Securities

The Company has no 5GI Securities as of December 31, 2023 and 2022.

P. Short Sales

The Company did not have any short sales at December 31, 2023 and 2022.

Q. Prepayment Penalty and Acceleration Fees

The Company did not have any prepayment penalty or acceleration fees at December 31, 2023.

R. Reporting Entity's Share of Cash Pool by Asset Type

The Company did not participate in a cash pool at December 31, 2023 or 2022.

6. Joint Ventures, Partnerships and Limited Liability Companies

- **A.** The Company has no investments in joint ventures, partnerships, or LLCs.
- **B.** Not applicable.

7. Investment Income

- **A.** All investment income due and accrued with amounts that are over 90 days past due is non-admitted.
- **B.** At December 31, 2023 and 2022 there was no nonadmitted accrued investment income.
- C. At December 31, 2023 and 2022 the gross, nonadmitted and admitted amounts for interest income due and accrued are as follows:

Interest Income Due and Accrued	2023	2022
1. Gross	\$ 1,692,264 \$	2,389,561
2. Nonadmitted	_	_
3. Admitted	1,692,264	2,389,561

- **D.** At December 31, 2023 and 2022 the Company had no aggregate deferred interest.
- **E.** At December 31, 2023 and 2022, the Company had no cumulative amounts of paid-in-kind ("PIK") interest included in the current principal balance.

8. Derivative Instruments

The Company has no derivative instruments.

9. Income Taxes

A. The components of net deferred tax assets (liabilities):

(1) The components of net deferred tax asset (liabilities) are as follows:

		12/31/2023		
		(1) (2)		(3)
		Ordinary	Capital	(Col 1+2) Total
(a)		* 12 120 500		
(a)	Gross Deferred Tax Assets	\$ 12,129,569	\$ 205,351	\$ 12,334,920
(b)	Statutory Valuation Allowance Adjustments	_	_	_
(c)	Adjusted Gross Deferred Tax Assets (1a - 1b)	12,129,569	205,351	12,334,920
(d)	Deferred Tax Assets Nonadmitted	_	_	_
(e)	Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	12,129,569	205,351	12,334,920
(f)	Deferred Tax Liabilities	15,331,313	324,246	15,655,559
(g)	Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	\$ (3,201,744)	\$ (118,895)	\$ (3,320,639)

12/31/2022				
(4)	(5)	(6)		
Ordinary	Capital	(Col 4+5) Total		

- (a) Gross Deferred Tax Assets
- (b) Statutory Valuation Allowance Adjustments
- (c) Adjusted Gross Deferred Tax Assets (1a 1b)
- (d) Deferred Tax Assets Nonadmitted
- (e) Subtotal Net Admitted Deferred Tax Asset (1c 1d)
- (f) Deferred Tax Liabilities
- (g) Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e 1f)

\$ 24,009,237 \$	250,894 \$	24,260,131
24,009,237	250,894	24,260,131
	_	
24,009,237	250,894	24,260,131
25,252,062	271,601	12,033,119
		-
\$ (1,242,825) \$	(20,707) \$	(1,263,532)

Change					
(7)	(8)	(9)			
(Col 1-4) Ordinary	(Col 2-5) Capital	(Col 7+8) Total			

- (a) Gross Deferred Tax Assets
- (b) Statutory Valuation Allowance Adjustments
- (c) Adjusted Gross Deferred Tax Assets (1a 1b)
- (d) Deferred Tax Assets Nonadmitted
- (e) Subtotal Net Admitted Deferred Tax Asset (1c 1d)
- (f) Deferred Tax Liabilities
- (g) Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e 1f)

\$(11,879,668) \$	(45,543) \$	(11,925,211)
	_	
(11,879,668)	(45,543)	(11,925,211)
	_	
(11,879,668)	(45,543)	(11,925,211)
(9,920,749)	52,645	(9,868,104)
\$ (1,958,919) \$	(98,188) \$	(2,057,107)

(2) The amount of admitted adjusted gross deferred tax assets under each component of SSAP No. 101, *Income Taxes* ("SSAP No. 101") are as follows:

		12/31/2023	
	(1)	(2)	(3)
	(-)	(-)	(Col 1+2)
	Ordinary	Capital	Total
Admission Calculation Components SSAP No. 101			
 (a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks. (b) Adjusted Gross Deferred Tax Assets Expected To Be Realized 	\$ 11,079,154	\$ —	\$ 11,079,154
 (b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below) 1. Adjusted Gross Deferred Tax Assets Expected To Be 	223,964	154,013	377,977
Realized Following the Balance Sheet Date.	223,964	154,013	377,977
Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold. (c) Adjusted Gross Deferred Tax Assets (Excluding The Amount	XXX	XXX	20,228,714
Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.	826,451	51,338	877,789
(d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))	\$ 12,129,569	\$ 205,351	\$ 12,334,920
		12/31/2022	
	(4)	(5)	(6)
	Ordinary	Capital	(Col 4+5) Total
Admission Calculation Components SSAP No. 101			
 (a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks. (b) Adjusted Gross Deferred Tax Assets Expected To Be Realized 	\$ 13,695,873	\$ 83,631	\$ 13,779,504
(Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below) 1. Adjusted Gross Deferred Tax Assets Expected To Be	8,987,608	167,263	9,154,871
Realized Following the Balance Sheet Date.	8,987,608	167,263	9,154,871
Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.	XXX	XXX	23,044,084
(c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.	1,325,756	_	1,325,756
(d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))	\$ 24,009,237	\$ 250,894	\$ 24,260,131
		Change	
	(7)	(8)	(9)
	(Col 1-4)	(Col 2-5)	(Col 7+8)
Administra Colombian Community SSARNI 101	Òrdinary	Capital	Total
Admission Calculation Components SSAP No. 101			
(a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.(b) Adjusted Gross Deferred Tax Assets Expected To Be Realized	\$ (2,616,719)	\$ (83,631)	\$ (2,700,350)
(Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)	(8,763,644)	(13,250)	(8,776,894)
 Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date. 	(8,763,644)	(13,250)	(8,776,894)
 Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold. 	XXX	XXX	(2,815,370)
(c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.	(499,305)	51,338	(447,967)
(d) Deferred Tax Assets Admitted as the result of application of $SSAP No. 101 Total (2(a) + 2(b) + 2(c))$	\$(11,879,668)		\$(11,925,211)
SSAP No. 101. Total $(2(a) + 2(b) + 2(c))$	ψ(11,079,000)	Ψ (+3,343)	ψ(11,743,411)

(3) 2023 2022 (a) Ratio Percentage Used To Determine Recovery Period And Threshold Limitation Amount. 519.36 % 687.18 % (b) Amount Of Adjusted Capital And Surplus Used To Determine Recovery Period And Threshold Limitation In 2(b)2 Above. 134,858,090 \$ 153,627,228 (4) 12/31/2023 12/31/2022 Change (1) **(4)** (2) (3) (5) (6)(Col 1-3) Ordinary (Col 2-4) **Ordinary Ordinary** Capital Capital Capital Impact of Tax-Planning Strategies Determination of Adjusted Gross Deferred Tax Assets and Net Admitted Deferred Tax Assets, By Tax Character As A Percentage. Adjusted Gross DTAs Amount From Note 9A1(c) \$12,129,569 \$205,351 \$24,009,237 \$250,894 \$(11,879,668) \$(45,543) Percentage of Adjusted Gross DTAs By Tax Character Attributable To The Impact Of Tax Planning Strategies 0.00 % 0.00~%0.00%0.00~%0.00~%0.00~%Net Admitted Adjusted Gross DTAs Amount From Note 9A1(e) \$12,129,569 \$205,351 \$24,009,237 \$250,894 \$(11,879,668) \$(45,543) Percentage of Net Admitted Adjusted Gross DTAs By Tax Character Admitted Because Of The Impact Of Tax 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % Planning Strategies (b) Does the Company's tax-planning strategies include the use of reinsurance? Yes No

B. The Company has no unrecognized deferred tax liabilities at December 31, 2023 and 2022.

C. Current income taxes incurred consist of the following major components:

Cui		it income taxes incurred consist of the following	,,,,	ing major	component	~ •
				(1)	(2)	(3)
				12/21/2022	12/21/2022	(Col 1-2)
(1)	Cur	rent Income Tax	_	12/31/2023	12/31/2022	Change
(1)						
		Federal	\$	9,847,846	\$ (993,635)	\$ 10,841,481
		Foreign Subtotal	_	9,847,846	(993,635)	10,841,481
	(c)	Subtotal Federal income tax expense on net capital gains				(2,122,870)
	(u) (e)			(2,170,024)	(75,754)	(2,122,670)
	(f)	Other		_	_	_
	. ,	Federal and foreign income taxes incurred	\$	7,649,022	\$ (1,069,589)	\$ 8,718,611
(2)	Def	erred Tax Assets:				
	(a)	<u> </u>				
		(1) Discounting of unpaid losses	\$	403,170		
		(2) Unearned premium reserve		766,918		101,508
		(3) Policyholder reserves		2,739,937	7,639,457	(4,899,520)
		(4) Investments (5) Deformed acquisition costs		_	_	_
		(5) Deferred acquisition costs(6) Policyholder dividends accrual		_	_	_
		(6) Policyholder dividends accrual(7) Fixed assets		110,138	377,752	(267,614)
		(8) Compensation and benefits accrual		110,136	426,812	(426,812)
		(9) Pension accrual		_		(120,012)
		(10) Receivables - nonadmitted		3,052,411	10,025,067	(6,972,656)
		(11) Net operating loss carry-forward			_	_
		(12) Tax credit carry-forward		_	_	_
		(13) Other		5,056,995	4,584,238	472,757
		(99) Subtotal (sum of 2a1 through 2a13)		12,129,569	24,009,237	
	(b)	Statutory valuation allowance adjustment		_	_	_
	(c)	Nonadmitted		_	_	
	(d)	Admitted ordinary deferred tax assets (2a99 - 2b - 2c)		12,129,569	24,009,237	(11,879,668)
	(e)	Capital				
		(1) Investments		205,351	250,894	(45,543)
		(2) Net capital loss carry-forward		_	_	_
		(3) Real estate		_	_	_
		(4) Other		_		
		(99) Subtotal (2e1+2e2+2e3+2e4)		205,351	250,894	(45,543)
	(f)	Statutory valuation allowance adjustment		_	_	_
	(g)	Nonadmitted	_			
	(h)	Admitted capital deferred tax assets (2e99 - 2f - 2g)	_	205,351	250,894	(45,543)
	(i)	Admitted deferred tax assets (2d + 2h)	\$	12,334,920	\$ 24,260,131	\$ (11,925,211)
(3)		erred Tax Liabilities:				
	(a)	Ordinary				
		(1) Investments	\$	_	\$ —	\$ —
		(2) Fixed assets		_	_	
		(3) Deferred and uncollected premium		_	_	_
		(4) Policyholder reserves		15 221 212	25 252 062	(0.020.740)
		(5) Other	_	15,331,313	25,252,062	(9,920,749)
	(1.)	(99) Subtotal (3a1+3a2+3a3+3a4+3a5)		15,331,313	25,252,062	(9,920,749)
	(b)	-				
		(1) Investments		_	_	_
		(2) Real estate(3) Other		324,246	271,601	52,645
		(3) Other (99) Subtotal (3b1+3b2+3b3)	_	324,246	271,601	52,645
	(0)	Deferred tax liabilities (3a99 + 3b99)	_	15,655,559		
(4)		deferred tax assets/liabilities (2i - 3c)	•		25,523,663	(9,868,104)
(4)	met	ueterieu tax assets/fiaulilities (21 - 30)	3	(3,320,639)	\$ (1,263,532)	\$ (2,057,107)

D. The Company's income tax expense and change in deferred income taxes differs from the amount obtained by applying the federal statutory income tax rate of 21% for the year ended December 31 as follows:

		2023	2022
Tax expense computed using federal statutory rate	\$	8,709,306 \$	11,399,097
Change in nonadmitted assets		(19,533)	(1,677,022)
Tax exempt income and dividend received deduction net of proration		(184,730)	(287,760)
Prior year true-up and adjustments		150,621	(638,686)
Tax settlements and contingencies		(3,727)	366,952
Other, net		1,086,540	(493,799)
Total	\$	9,738,477 \$	8,668,782
Federal income taxes incurred	\$	7,649,022 \$	(1,069,589)
Change in net deferred income taxes		2,089,455	9,738,371
Total statutory income taxes	\$	9,738,477 \$	8,668,782
	•		

E. Operating loss carryforwards:

- (1) The Company has no operating loss carryforwards and no corporate alternative minimum tax ("AMT") credit carryforwards as of December 31, 2023 or 2022.
- (2) The following are income taxes incurred in the current and prior year(s) that will be available for recoupment in the event of future net losses:

	Ordinary	Capital	Total
2023	\$ 12,543,942	\$ - \$	12,543,942
2022	_	_	_
2021	N/A	_	_

- (3) The Company has no protective tax deposits reported as admitted assets under Section 6603 of the Internal Revenue Service Code as of December 31, 2023 and 2022.
- F. The following companies will be included in the consolidated federal income tax return with their parent Elevance Health, Inc. ("Elevance Health") as of December 31, 2023 and either are current members of the consolidated tax sharing agreement or are in the process of being added to the consolidated tax sharing agreement. Allocation of federal income taxes, including corporate AMT, with affiliates subject to the tax sharing agreement is based upon separate income tax return calculations, including separate corporate AMT calculations, with credit for net operating losses and capital losses that can be used on a consolidated basis. Pursuant to this agreement, the Company has the enforceable right to recoup federal income taxes paid in prior years in the event of future net losses, which it may incur, or to recoup its net losses carried forward as an offset to future net income subject to federal income taxes. Intercompany income tax balances are settled based on the Internal Revenue Service due dates.

Alliance Care Management, LLC DeCare Dental, LLC AMERIGROUP Community Care of New Mexico, Inc. Designated Agent Company, Inc. EHC Benefits Agency, Inc. Amerigroup District of Columbia, Inc. Amerigroup Mississippi, Inc. Elevance Health Inc Amerigroup Oklahoma, Inc. Empire HealthChoice Assurance, Inc. Amerigroup Pennsylvania, Inc. Empire HealthChoice HMO, Inc. AMGP Georgia Managed Care Company, Inc. Federal Government Solutions, LLC Anthem Blue Cross Life and Health Insurance Company FHC Health Systems, Inc. Anthem Financial, Inc. Freedom Health, Inc. Anthem Health Plans of Kentucky, Inc. Freedom SPV. Inc. Anthem Health Plans of Maine, Inc. Golden West Health Plan, Inc. Anthem Health Plans of New Hampshire, Inc. Healthkeepers, Inc. Anthem Health Plans of Virginia, Inc. HealthLink Administrators, Inc. HealthLink Inc Anthem Health Plans, Inc.

Anthem Holding Corp. HealthPlus HP, LLC
Anthem Insurance Companies, Inc. HealthSun Health Plan, Inc.

Anthem Kentucky Managed Care Plan, Inc. Healthy Alliance Life Insurance Company

Anthem Southeast, Inc.

APR, LLC

HMO Colorado, Inc.

Arcus Enterprises, Inc.

HMO Missouri, Inc.

Aspire Health, Inc.

IEC Group Holdings, Inc.

Associated Group, Inc. IEC Group, Inc. d/b/a AmeriBen

AUMSI UM Services, Inc. Imaging Management Holdings, LLC

Beacon Health Financing, LLC Living Complete Technologies, Inc.

Beacon Health Options Holdco, Inc.

Massachusetts Behavioral Health Partnership

Missouri Care, Incorporated

Beacon Health Vista Parent, Inc. Matthew Thornton Health Plan, Inc.

Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. myNEXUS Holdings, Inc.

BioPlus Parent, LLC

Blue Cross Blue Shield of Wisconsin myNEXUS Management, Inc.
Blue Cross of California Nash Holding Company, LLC

Blue Cross of California Partnership Plan, Inc.

National Government Services, Inc.

Carelon Behavioral Care, Inc.

New England Research Institutes, Inc.

Carelon Behavioral Health, Inc.

Carelon Behavioral Health IPA, Inc.

Carelon Behavioral Health of California, Inc.

Carelon Behavioral Health of California, Inc.

RightCHOICE Managed Care, Inc.

Carelon Behavioral Health Strategies IPA, LLC Rocky Mountain Hospital and Medical Service, Inc.

Carelon Digital Platforms, Inc. SellCore, Inc.

Carelon Global Solutions U.S., Inc.

Carelon Health Federal Services, Inc.

Carelon Health of New Jersey, Inc.

Simply Healthcare Plans, Inc.

Southeast Services, Inc.

State Sponsored Services, Inc.

Carelon Health of Pennsylvania, Inc.

The Elevance Health Companies, Inc.

Carelon Health Solutions, Inc.

The Elevance Health Companies of California, Inc.

Carelon Holdings, Inc.

TrustSolutions, LLC

Carelon Holdings I, Inc.

UNICARE Health Plan of West Virginia, Inc.

Carelon Insights, Inc.

Carelon Medical Benefits Management, Inc.

Carelon PharmacyRx, Inc.

UNICARE Illinois Services, Inc.

UNICARE National Services, Inc.

UNICARE Specialty Services, Inc.

Carelon Post Acute Solutions, Inc.

ValueOptions Texas, Inc.

Carelon Research, Inc. WellPoint California Services, Inc.

CarelonRx, Inc.

CareMore Health IPA of New York, Inc.

CareMore Health of Arizona, Inc.

CareMore Health Plan

CareMore Health Plan of Arizona, Inc.

WellPoint Dental Services, Inc.

WellPoint Federal Corporation

WellPoint Health Solutions, Inc.

CareMore Health Plan of Nevada, Inc.

WellPoint Holding Corporation

CareMore Health Plan of Texas, Inc. WellPoint Information Technology Services, Inc.

CareMore Health System Wellpoint Insurance Company
Cerulean Companies, Inc. WellPoint Insurance Services, Inc.

Claim Management Services, Inc. Wellpoint Iowa, Inc.

Community Care Health Plan of Kansas, Inc.

Wellpoint Life and Health Insurance Company

Community Care Health Plan of Nebraska, Inc.

Wellpoint Maryland, Inc.

Community Care Health Plan of Nevada, Inc.

Wellpoint New Jersey, Inc.

Community Insurance Company

Wellpoint Ohio, Inc.

Compcare Health Services Insurance Corporation Wellpoint South Carolina, Inc.

Crossroads Acquisition Corp. Wellpoint Tennessee, Inc.

DeCare Analytics, LLC Wellpoint Texas, Inc.

DeCare Dental Health International, LLC Wellpoint Washington, Inc.

DeCare Dental Networks, LLC Wisconsin Collaborative Insurance Company

G. Not applicable.

H. Repatriation Transition Tax (RTT)

Not applicable.

I. Alternative Minimum Tax (AMT) Credit

(1) On August 16, 2022, the U.S. government enacted the Inflation Reduction Act which includes a new corporate AMT of 15% on the adjusted financial statement of income ("AFSI") of corporations with average AFSI exceeding \$1.0 billion over a three-year period. The corporate AMT is effective beginning after December 31, 2022. The controlled group of corporations, of which the Company is a member, has determined it is an applicable corporation for purposes of determining if the corporate AMT exceeds the regular federal income tax payable. The controlled group has determined that it does not expect to be subject to the corporate AMT in 2023.

The Company is an applicable reporting entity, not individually as an unaffiliated corporation, but as a member of a tax-controlled group of corporations. The Company does not expect to be subject to the corporate AMT in 2023.

- (2) An accounting policy election has been made to disregard corporate AMT when evaluating the need for a valuation allowance for its regular tax deferred tax assets.
- (3) The controlled group of corporations, of which the Company is a member, has not made any material modifications to the methodology used to project the corporate AMT liability.
- (4) Does the Company's tax-planning strategies include the use of corporate AMT? Yes_____ No _X__

10. Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

A. Nature of the Relationship

The Company is a Maine domiciled stock insurance company and is a wholly-owned subsidiary of ATH Holding Company, LLC ("ATH Holding") which is a wholly-owned subsidiary of Elevance Health, a publicly traded company.

B. Significant Transactions for Each Period

The following significant transactions took place between the Company and its affiliates:

The Board of Directors of the Company declared an ordinary dividend in the amount of \$49,000,000 on December 15, 2023. The Company paid the dividend to its parent company, ATH Holding, on December 28, 2023.

The Board of Directors of the Company declared an ordinary dividend in the amount of \$29,200,000 on December 15, 2022. The Company paid the dividend to its parent company, ATH Holding, on December 28, 2022.

C. Transactions with Related Parties who are not Reported on Schedule Y

The Company has no transactions with related parties who are not reported on Schedule Y.

D. Amounts Due to or from Related Parties

At December 31, 2023 and 2022, the Company reported no amounts due from affiliates. At December 31, 2023 and 2022, the Company reported \$54,745,026 and \$130,122,304 due to affiliates, respectively. The receivable and payable balances represent intercompany transactions that will be settled in accordance with the settlement terms of the intercompany agreement.

Following is a summary of transactions between the Company and various affiliates during the years:

	2023	2022
The Elevance Health Companies, Inc.		
Payroll and Employee Administrative Services	\$ 59,933,053	\$ 64,008,919
Elevance Health, Inc.		
Federal Income Tax Payments	6,532,399	20,182,860
Corporate Services	22,676,536	25,881,624
Information Technology Services	3,351,247	3,623,345
Anthem Insurance Companies, Inc.		
Information Technology Services		622
Corporate Services	445,049	497,125
WellPoint Information Technology Services, Inc.		
Information Technology Services	3,908,844	4,541,236
Corporate Services	1,198,493	602,471
Blue Cross of California		
Corporate Services	32,503	44,992
Information Technology Services	134	56
Anthem Health Plans, Inc.		
Claims Processing	39,649	3,305
Corporate Services	(16,288)	15,554
Anthem Health Plans of New Hampshire, Inc.		
Corporate Services	(144)	(2,573)
Anthem Health Plans of Virginia, Inc.		
Information Technology Services	1,981	2,425
Corporate Services	(71,252)	(76,591)
Costs allocated from other Elevance Health, Inc. affiliates not listed above	1,453,206	1,050,838
Total Schedule Y, Part 2, Column 8	\$ 99,485,410	\$ 120,376,208

E. Management and Service Contracts and Cost Sharing Arrangements

The Company entered into risk sharing arrangements with affiliated companies within Elevance Health's Carelon Services division in 2023. The Company reported \$4,018 of incentive payments as claims expense under these arrangements in 2023.

The Company has entered into administrative services agreements with its affiliated companies. Pursuant to these agreements, various administrative, management and support services are provided to or provided by the Company. The costs and expenses related to these administrative management and support services are allocated to or allocated by the Company in an amount equal to the direct and indirect costs and expenses incurred in providing these services. Costs include expenses such as salaries, employee benefits, information technology, pharmacy benefits administration, communications, advertising, consulting services, rent, utilities, billing, accounting, underwriting, and product development, which support the Company's operations. These costs are allocated based on various utilization statistics.

In addition, the Company is party to the Fair Market Value ("FMV") Services Attachment, to the master administrative services agreement with affiliates, the costs and expenses related to certain services including behavioral health, palliative care, utilization management, payment integrity services, subrogation services as well as health and

wellness programs are allocated to or allocated by the Company in an amount equal to the fair market value of the services provided. These costs are allocated based on various utilization statistics.

The FMV Services Attachment was amended to add BioPlus Specialty Pharmacy Services, LLC and BioPlus Parent, LLC as a provider effective August 1, 2023.

The Company is party to a cash concentration agreement with its affiliated companies. Under this agreement, any of the Company's affiliates may be designated as a cash manager to handle the collection and/or payment of funds on behalf of the Company. Conversely, the Company may be designated as a cash manager to handle the collection and/or payment of funds on behalf of its affiliates. Cash services covered under this agreement include the collection of premiums and other revenue, the collection of benefit and administrative expense reimbursements, the payment of policy benefits, payroll expense, general and administrative expense, and accounts payable disbursements.

There were no changes to the intercompany management and service arrangements, and there were no additional arrangements entered into during 2023 or 2022. The amounts of transactions under such agreements are presented in Schedule Y, Part 2.

F. Guarantees or Contingencies for Related Parties

The Company did not enter into guarantees or undertakings for the benefit of an affiliate which would result in a material contingent exposure of the Company's or any affiliated insurer's assets or liabilities.

G. Nature of Control Relationships that Could Affect Operations or Financial Position

ATH Holding owns all outstanding shares of the Company. The Company's ultimate parent is Elevance Health.

H. Amount Deducted for Investment in Upstream Company

The Company does not own shares of upstream intermediate entities or Elevance Health.

I. Detail of Investments in Affiliates Greater than 10% of Admitted Assets

At December 31, 2023 and 2022, the Company did not have investments in affiliates.

J. Write-down for Impairments of Investments in Subsidiaries, Controlled or Affiliated ("SCA") Companies

Not applicable.

K. Investment in a Foreign Insurance Subsidiary

The Company does not have investments in foreign insurance subsidiaries.

L. Investment in Downstream Non-insurance Holding Companies

The Company does not have investments in downstream non-insurance holding companies.

M. All SCA Investments

The Company has no SCA Investments.

N. Investment in Insurance SCAs

The Company does not have investments in Insurance SCAs.

O. SCA or SSAP 48 Entity Loss Tracking

The Company does not have losses on investments in Insurance SCAs and/or joint ventures, partnerships or LLCs.

11. Debt

A. Capital Notes and Other Debt

The Company had no capital notes or other debt outstanding at December 31, 2023 and 2022.

B. FHLB (Federal Home Loan Bank) Agreements

The Company had no FHLB agreements outstanding at December 31, 2023 and 2022.

C. All Other Debt

The Company had no other debt outstanding at December 31, 2023 and 2022.

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

A. Defined Benefit Plan

Not applicable - See Note 12G.

- **B.** Not applicable See Note 12G.
- C. Not applicable See Note 12G.
- **D.** Not applicable See Note 12G.

E. Defined Contribution Plans

Not applicable - See Note 12G.

F. Multiemployer Plans

The Company does not participate in a multiemployer plan.

G. Consolidated/Holding Company Plans

The Company participates in the Elevance Health Cash Balance Plan A and the Elevance Health Cash Balance Plan B, collectively referred to as "the Cash Balance Plans." The Cash Balance Plans are frozen non-contributory defined benefit pension plans sponsored by ATH Holding, covering certain eligible employees of Elevance Health and its subsidiaries. ATH Holding allocates a share of the total accumulated costs of the plans to the Company based on the number of allocated employees. The Company has no legal obligation for benefits under these plans.

The Company participates in a postretirement medical benefit plan, sponsored by ATH Holding, providing certain medical, vision and dental benefits to eligible retirees. ATH Holding allocates a share of the total accumulated costs of this plan to the Company

based on the number of allocated employees. The Company has no legal obligation for benefits under this plan.

The Company participates in a nonqualified deferred compensation plans sponsored by Elevance Health which covers certain employees once the participant reaches the maximum contribution amount for the Elevance Health 401(k) Plan (the "401(k) Plan"). The deferred amounts are payable according to the terms and subject to the conditions of the deferred compensation plan. Elevance Health allocates a share of the total accumulated costs of this plan to the Company based on the number of allocated employees subject to the deferred compensation plan. The Company has no legal obligation for benefits under this plan.

The Company participates in the 401(k) Plan, sponsored by ATH Holding and covering substantially all employees. Voluntary employee contributions are matched by ATH Holding subject to certain limitations. ATH Holding allocates a share of the total accumulated costs of this plan to the Company based on the number of allocated employees. The Company has no legal obligation for benefits under this plan.

The Company participates in a stock incentive compensation plan, sponsored by Elevance Health, providing incentive awards to non-employee directors and employees, consisting of Elevance Health stock options, restricted stock, restricted stock units, stock appreciation rights, performance shares, and performance units. Elevance Health allocates a share of the total share-based compensation expense of this plan to the Company based on the number of allocated employees. The Company has no legal obligation for benefits under this plan.

During 2023 and 2022, the Company was allocated the following costs or (credits) for these retirement benefits:

	 2023	2022
Defined benefit pension plan	\$ 32,266 \$	(109,266)
Postretirement medical benefit plan	(47,194)	(68,034)
Deferred compensation plan	14,532	10,097
Defined contribution plan	1,324,855	1,040,378
Stock incentive compensation plan	1,369,243	1,159,762

H. Post Employment Benefits and Compensated Absences

Not applicable.

I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17)

Not applicable.

13. Capital and Surplus, Shareholders' Dividend Restrictions and Quasi-Reorganizations

A. Outstanding Shares

As of December 31, 2023, the Company has 2,500 shares of \$1,000 par value common stock authorized, issued and outstanding.

B. Preferred Stock

The Company has no preferred stock outstanding.

C. Dividend Restrictions

Under Maine law, the Company is limited in the amount of dividends that can be declared without regulatory approval. The Superintendent of Insurance must approve any

dividend that, together with all dividends declared during the preceding twelve months, exceeds the greater of the net gain from operations for the twelve-month period ending December 31 of the preceding year or 10% of the Company's surplus to policyholders as of December 31 of the preceding year as long as unassigned surplus is positive. Also, any dividend paid from other than unassigned funds will need the approval of the Superintendent of Insurance.

D. Dividends Paid

See Footnote 10B.

E. Maximum Ordinary Dividend During 2024

Within the limitations of (C) above, the Company may pay \$7,090,327 in ordinary dividends during 2024 without restrictions, other than state notification requirements.

F. Unassigned Surplus Restrictions

Unassigned surplus funds are not restricted at December 31, 2023.

G. Mutual Surplus Advances

Not applicable.

H. Company Stock Held for Special Purpose

There are no shares of stock held for special purposes at December 31, 2023.

I. Changes in Special Surplus Funds

The change in balances of special surplus funds from the prior year are due to changes in the amounts segregated for the deferred gain on the Company's sale-leaseback transaction.

J. Changes in Unassigned Funds

The portion of unassigned funds represented by cumulative unrealized investment gains and losses was (\$121,691) at December 31, 2023.

K. Surplus Notes

The Company has not issued any surplus notes or debentures or similar obligations.

L. Restatement due to Prior Quasi-reorganizations

The Company had no restatements due to prior quasi-reorganizations.

M. Quasi-reorganizations over Prior 10 Years

The Company has not been involved in a quasi-reorganization during the past 10 years.

14. Liabilities, Contingencies and Assessments

A. Contingent Commitments

The Company had no contingent commitments at December 31, 2023 or 2022.

B. Assessments

(1) The Company is subject to guaranty fund and other assessments by the state(s) in which it writes business. Guaranty fund assessments are accrued at the time of covered insurer insolvencies. Other assessments are accrued at the time the assessment obligation is incurred.

(2) Guaranty Fund Assets Recognized Reconciliation

	tax offsets and policy surcharges prior year-end	\$ 86,765
b.	Decreases current year:	
	Policy surcharges collected	_
	Policy surcharges charged off	_
	Premium tax offset applied	33,429

c. Increases current year:

Policy surcharges recognized —
Premium tax offset recognized (53,336)

d. Guaranty fund assets recognized from paid and accrued premium tax offsets and policy surcharges current year-end

a. Guaranty fund assets recognized from paid and accrued premium

\$ —

(3) Not applicable.

C. Gain Contingencies

The Company has no gain contingencies at December 31, 2023 or 2022.

D. Claims-Related Extra Contractual Obligation and the Bad Faith Losses Stemming From Lawsuits

Not applicable.

E. Joint and Several Liabilities

Not applicable.

F. All Other Contingencies

Guaranty fund assessments

The National Organization of Life & Health Insurance Guaranty Associations, or NOLHGA, is a voluntary organization consisting of the state life and health insurance guaranty associations located throughout the U.S. Such associations, working together with NOLHGA, provide a safety net for their state's policyholders, ensuring that they continue to receive coverage, subject to state maximum limits, even if their insurer is declared insolvent. Under insolvency or guaranty association laws, insurance companies can be assessed for amounts paid by guaranty funds for policyholder losses incurred when an insurance company becomes insolvent. State insolvency or guaranty association laws currently provide for assessments based upon the amount of premiums received on insurance underwritten within such state (with a minimum amount payable even if no premium is received). Under these guaranty association laws, assessments are made retrospectively.

In March 2017, long term care insurance writers Penn Treaty Network America Insurance Company and its subsidiary American Network Insurance Company, (collectively "Penn Treaty"), were ordered to be liquidated by the Pennsylvania state court, which had

jurisdiction over the Penn Treaty rehabilitation proceeding. The Company and other insurers have paid state guaranty association assessments and may be obligated to pay additional assessments to cover Penn Treaty policyholder claims. Payment of these assessments are largely recovered through premium tax credits over future years.

Litigation and regulatory proceedings

Blue Cross Blue Shield Antitrust Litigation

Elevance Health, Inc. is a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees (the "Blue plans") across the country. Cases filed in twenty-eight states were consolidated into a single, multi-district proceeding captioned *In re Blue Cross Blue Shield Antitrust Litigation* that is pending in the U.S. District Court for the Northern District of Alabama (the "Court"). Generally, the suits allege that the BCBSA and the Blue plans have conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions, rules governing the BlueCard® and National Accounts programs and other arrangements in violation of the Sherman Antitrust Act ("Sherman Act") and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers.

In April 2018, the Court issued an order on the parties' cross motions for partial summary judgment, determining that the defendants' aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard® program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. With respect to whether the defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks, the Court found that summary judgment was not appropriate due to the existence of genuine issues of material fact. In April 2019, the plaintiffs filed motions for class certification, which defendants opposed.

The BCBSA and Blue plans approved a settlement agreement and release with the subscriber plaintiffs (the "Subscriber Settlement Agreement"), which agreement required the Court's approval to become effective. The Subscriber Settlement Agreement requires the defendants to make a monetary settlement payment and contains certain terms imposing non- monetary obligations including (i) eliminating the "national best efforts" rule in the BCBSA license agreements (which rule limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan.

In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to opt out of the class. A small number of subscribers submitted valid opt-outs by the July 2021 opt-out deadline.

In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the "Final Approval Order"). The Court amended its Final Approval Order in September 2022, further clarifying the injunctive relief that may be available to subscribers who submitted valid opt-outs. In September 2022, an objector filed a motion to amend the Final Approval Order, which the Court denied. In compliance with the Subscriber Settlement Agreement, Elevance Health paid \$506,000,000 into an escrow account in September 2022, for an aggregate and full settlement payment by Elevance Health of \$596,000,000, which amount was accrued in 2020.

Four notices of appeal of the Final Approval Order were filed by the September 2022 appeal deadline. Those appeals were heard by a panel of the United States Court of Appeals for the Eleventh Circuit in September 2023. In October 2023, the Eleventh Circuit affirmed the District Court's order approver the subscriber settlement. Certain appellants filed petitions for rehearing in November 2023 and December 2023. In the event that all appellate rights are exhausted in a manner that affirms the Court's Final Approval Order, the defendants' payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective and the funds held in escrow will be distributed in accordance with the Subscriber Settlement Agreement.

In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for class certification, which defendants opposed. In March 2021, the Court issued an order terminating the pending motion for class certification until the Court determined the standard of review applicable to the providers' claims. In response to that order, the parties filed renewed standard of review motions in May 2021. In June 2021, the parties filed summary judgment motions not critically dependent on class certification. In February 2022, the Court issued orders (i) granting certain defendants' motion for partial summary judgment against the provider plaintiffs who had previously released claims against such defendants, and (ii) granting the provider plaintiffs' motion for partial summary judgment, holding that Ohio v. American Express Co. does not affect the standard of review in this case. In August 2022, the Court issued orders (i) granting in part the defendants' motion regarding the antitrust standard of review, holding that for the period of time after the elimination of the "national best efforts" rule, the rule of reason applies to the provider plaintiffs' market allocation conspiracy claims, and (ii) denying the provider plaintiffs' motion for partial summary judgment on the standard of review, reaffirming its prior holding that the providers' group boycott claims are subject to the rule of reason. In December 2023, the Court denied Defendants' Motion for Summary Judgment on Providers' Damage Claims as Time-Barred and Speculative and Provider Plaintiffs' Motion for partial Summary Judgment on the Defendants' Single Entity Defense due to the existence of genuine issues of material fact. Providers Plaintiffs' motion for class certification remain pending. Elevance Health intends to continue to vigorously defend the provider litigation, which they believe is without merit, however, its ultimate outcome cannot be presently determined.

A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed. Those actions are: Alaska Air Group, Inc., et al. v. Anthem, Inc., et al., No. 2:21-cv-01209-AMM (N.D. Ala.); JetBlue Airways Corp., et al. v. Anthem, Inc., et al., No. 2:22-cv-00558-GMB (N.D. Ala.); Metropolitan Transportation Authority v. Blue Cross and Blue Shield of Alabama et al., No. 2:22-cv-00265-RDP (N.D. Ala.) (dismissed without prejudice on June 27, 2023); Bed Bath & Beyond Inc. v. Anthem, Inc., No. 2:22-cv-01256-SGC (N.D. Ala.); Hoover, et al. v. Blue Cross Blue Shield Association, et al., No. 2:22-cv-00261-RDP (N.D. Ala.); and VHS Liquidating Trust v. Blue Cross of California, et al., No. RG21106600 (Cal. Super.). In February 2023, the Court denied the defendents' motion to dismiss based on a statute of limitations defense in Alaska Air and Jet Blue. On September 14, 2023, the VHS Court upheld its prior order granting in part Defendants' motion to strike based on the statute of limitations. Elevance Health intends to continue to vigorously defend these follow-on cases, which they believe are without merit; however, their ultimate outcome cannot be presently determined.

Express Scripts, Inc. Pharmacy Benefit Management Litigation

In March 2016, Elevance Health, Inc. filed a lawsuit against Express Scripts, Inc. ("Express Scripts"), their vendor at the time for PBM services, captioned *Anthem, Inc. v. Express Scripts, Inc.*, in the U.S. District Court for the Southern District of New York (the "District Court"). The lawsuit seeks to recover over \$14,800,000,000 in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement

between the parties (the "ESI Agreement"), over \$158,000,000 in damages related to operational breaches, as well as various declarations under the ESI Agreement, including that Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) was required to provide competitive benchmark pricing to Elevance Health through the term of the ESI Agreement; (iii) has breached the ESI Agreement; and (iv) is required under the ESI Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination.

Express Scripts has disputed Elevance Health's contractual claims and is seeking declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI Agreement, and (ii) that it has no obligation to ensure that Elevance Health receives any specific level of pricing, that Elevance Health has no contractual right to any change in pricing under the ESI Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that Elevance Health has been unjustly enriched by its payment of \$4,675,000,000 at the time they entered into the ESI Agreement. In March 2017, the District Court granted Elevance Health's motion to dismiss Express Scripts' counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. After such ruling, Express Scripts' only remaining claims were for breach of contract and declaratory relief. In August 2021, Express Scripts filed a motion for summary judgment, which Elevance Health opposed. In March 2022, the District Court granted in part and denied in part Express Scripts' motion for summary judgment. The District Court dismissed Elevance Health's declaratory judgment claim, Elevance Health's breach of contract claim for failure to prove damages and most of Elevance Health's operational breach claims. As a result of the summary judgment decision, the only remaining claims as of the filing of this Annual Report are (i) Elevance Health's operational breach claim based on Express Scripts' prior authorization processes and (ii) Express Scripts' counterclaim for breach of the market check provision of the ESI Agreement. Express Scripts filed a second motion for summary judgment in June 2022, challenging Elevance Health's remaining operational breach claims, which Elevance Health opposed, and the District Court denied in March 2023, allowing Elevance Health's operational breach claim to proceed. In November 2023, the Court issued an Order ending the lawsuit as a result of the parties entering into a settlement agreement. In December 2023, Elevance Health filed a notice of appeal with the United States Court of Appeal for the Second Circuit, regarding the pricing case. The Appellate Court recently ordered the parties to mediate the pricing case in February 2024. The ultimate outcome of this appeal cannot be presently determined.

Medicare Risk Adjustment Litigation

In March 2020, the U.S. Department of Justice ("DOJ") filed a civil lawsuit against Elevance Health, Inc. in the U.S. District Court for the Southern District of New York (the "New York District Court") in a case captioned United States v. Anthem, Inc. The DOJ's suit alleges, among other things, that Elevance Health falsely certified the accuracy of the diagnosis data they submitted to the Centers for Medicare and Medicaid Services ("CMS") for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, Elevance Health caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled Elevance Health to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July 2020, alleging the same causes of action but revising some of its factual allegations. In September 2020, Elevance Health filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in the amended complaint, all of which the New York District Court denied in October 2022. In November 2022, Elevance Health filed an answer. In March 2023, discovery commenced, and an initial case management conference was held in April 2023. The Court entered a scheduling order requiring fact discovery to be completed by June 2024 and expert discovery to be

complete by February 2025. Elevance Health intends to continue to vigorously defend this suit, which they believe is without merit; however, the ultimate outcome cannot be presently determined.

Other Contingencies

From time to time, the Company and certain of its subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. The Company, like Health Maintenance Organizations ("HMOs") and health insurers generally, exclude certain healthcare and other services from coverage under their HMO, Preferred Provider Organizations and other plans. The Company is, in the ordinary course of business, subject to the claims of their enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on the Company. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims.

In addition to the lawsuits described above, the Company is also involved in other pending and threatened litigation of the character incidental to their business and is from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on the Company's business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on the Company's consolidated financial position or results of operations.

The Company has no other known material contingencies.

Provisions for uncollectible amounts

At December 31, 2023 and 2022, the Company reported admitted assets of \$121,361,853 and \$191,426,602, respectively, in premium receivables and receivables due from uninsured plans. Based upon the Company's experience, any uncollectible receivables are not expected to exceed \$25,311,381 that was nonadmitted at December 31, 2023; therefore, no additional provision for uncollectible amounts has been recorded. The potential for any additional loss is not believed to be material to the Company's financial condition.

15. Leases

A. Lessee Operating Lease

(1) The Company leases office space, office equipment, EDP equipment, and software under various noncancelable operating leases Certain leases have the right to renew. There are no escalation clauses for any lease. Related lease expense for 2023 and 2022 was \$501,820 and \$135,605, respectively.

The Company reevaluated its future office space needs and determined that it would permanently cease use of space under certain operating leases. At December 31, 2023 and 2022, the Company has lease exit costs liabilities of \$6,636,395 and \$7,695,044, respectively, included in general expenses due or accrued on the balance sheet.

(2) At December 31, 2023, the minimum aggregate rental commitments are as follows:

	Year Ending December 31	Operating Leases				
1.	2024	\$	1,837,660			
2.	2025		1,837,660			
3.	2026		1,837,660			
4.	2027		1,071,968			
5.	Thereafter		<u> </u>			
6.	Total (sum of 1 through 5)	\$	6,584,948			

(3)

- a. During 2015, the Company entered into a sale-leaseback transaction with an unaffiliated entity to lease the South Portland, Maine building for 12 years.
- b. Not applicable.

B. Lessor Leases

- (1) The Company has not entered into any operating leases as a lessor.
- (2) The Company has not entered into any leveraged leases.

16. Information About Financial Instruments With Off-Balance Sheet Risk and Financial Instruments With Concentrations of Credit Risk

The Company has no significant financial instruments with off-balance sheet risk.

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of investment securities. All investment securities are managed by professional investment managers within policies authorized by the board of directors. Such policies limit the amounts that may be invested in any one issuer and prescribe certain investee company criteria. As of December 31, 2023, there were no significant concentrations.

17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

A. Transfers of Receivables Reported as Sales

Not applicable at December 31, 2023 and 2022.

B. Transfer and Servicing of Financial Assets

- (1) The Company participates in a securities lending program whereby marketable securities in its investment portfolio are transferred to independent brokers or dealers. At December 31, 2023 the fair value of securities loaned was \$10,198,433 and the carrying value of securities loaned was \$9,486,306
- (2) (7) Not applicable.

C. Wash Sales

- (1) In the course of the Company's asset management, securities may be sold and reacquired within 30 days of the sale date to enhance the yield on the investments.
- (2) At December 31, 2023 and 2022, there were no wash sales involving securities with an NAIC designation of 3 or below or unrated.

18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

A. Administrative Services Only ("ASO") Plans

The gain or (loss) from operations from ASO uninsured plans and the uninsured portion of partially insured plans during 2023 was:

		AS	O Uninsured Plans	U	ninsured Portion of Partially Insured Plans	Total ASO
a.	Net reimbursement for administrative expenses (including administrative fees) in excess of (less than) actual expenses	\$	213,672	\$	— \$	213,672
b.	Total net other income or expenses (including interest paid to or received from plans)		_		_	
c.	Net gain or (loss) from operations	\$	213,672	\$	— \$	213,672
d.	Total claim payment volume	\$	43,300,877	\$	— \$	43,300,877

B. Administrative Services Contract ("ASC") Plans

The gain or (loss) from operations from ASC uninsured plans and the uninsured portion of partially insured plans during 2023 was:

		AS	SC Uninsured Plans	Uninsured Portion of Partially Insured Plans	Total ASC
a.	Gross reimbursement for medical cost incurred	\$	439,574,118	\$	\$ 439,574,118
b.	Gross administrative fees accrued		29,369,036	_	29,369,036
c.	Other income or expenses (including interest paid to or received from plans)		_	_	_
d.	Gross expenses incurred (claims and administrative)		(463,452,310)	_	(463,452,310)
e.	Total gain or (loss) from operations	\$	5,490,844	\$ —	\$ 5,490,844
	5 ()		,	<u> </u>	 , , -

C. Medicare or Other Similarly Structured Cost-Based Reimbursement Contract

(1) The Company does not record revenue explicitly attributable to the cost share and reinsurance components of administered Medicare products.

(2)

Receivable from	Related to	2023	2022
Federal government	ACA and Medicare cost sharing and reinsurance programs	\$ 946,533	\$ 5,175
State government	ACA cost sharing and reinsurance programs, including Section 1332	\$ 5,575,655	\$ 6,886,164
Uninsured plans	Uninsured business, not including pharmaceutical rebate or provider receivables	\$ 45,650,422	\$ 109,194,789

- (3) As no revenue is recorded in connection with the cost share and reinsurance components of the Company's Medicare and ACA products, the Company has recorded no allowances and reserves for the adjustment of recorded revenues and receivables.
- (4) The Company has made no adjustment to revenue resulting from the audit of cost-reimbursement receivables related to revenues recorded in the prior period.

19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

No premiums were written by managing general agents or third party administrators during the years ended December 31, 2023 and 2022.

20. Fair Value Measurements

A.

(1) Fair Value Measurements at Reporting Date

Description for each class of asset or liability	(L	evel 1)	(Level 2)	(Lev	vel 3)	Net Asset Value (NAV)	Total
a. Assets at fair value							
Bonds							
Industrial and misc	\$	_	\$ 2,287,615	\$	_	\$	\$2,287,615
Total bonds	\$	_	\$ 2,287,615	\$	_	\$ —	\$2,287,615
Total assets at fair value/NAV	\$		\$ 2,287,615	\$		\$	\$2,287,615

(2) Fair Value Measurements in (Level 3) of the Fair Value Hierarchy

There are no investments in Level 3 as of December 31, 2023 and 2022.

- (3) The Company's policy is to recognize transfers between Levels, if any, as of the beginning of the reporting period.
- (4) Fair values of bonds are based on quoted market prices, where available. These fair values are obtained primarily from third party pricing services, which generally use Level 1 or Level 2 inputs, for the determination of fair value to facilitate fair value measurements and disclosures. Level 2 securities primarily include United States government securities, corporate securities, securities from states, municipalities and political subdivisions, mortgage-backed securities and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. The Company has controls in place to review the pricing services' qualifications and procedures used to determine fair values. In addition, the Company periodically reviews the pricing services' pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable.

Certain bonds, primarily corporate debt securities, are designated Level 3. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.

There have been no significant changes in the valuation techniques during the current period.

B. Fair Value Measurements Under Other Accounting Pronouncements

Not applicable at December 31, 2023 and 2022.

C. Financial Instruments

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Practicable (Carrying Value)
Bonds	\$278,132,797	\$296,631,138	\$ —	\$278,132,797	\$ —	\$ —	\$ —
Securities lending collateral asset	10,450,909	10,441,966	_	10,450,909	_	_	_

Not

D. Not Practicable to Estimate Fair Value

There are no financial instruments that were not practicable to estimate fair value.

E. Investments Measured at Net Asset Value

The Company has no investments measured at net asset value.

21. Other Items

A. Unusual or Infrequent Items

Not applicable at December 31, 2023 and 2022.

B. Troubled Debt Restructuring: Debtors

Not applicable at December 31, 2023 and 2022.

C. Other Disclosures

Land is recorded at cost and other real estate is recorded at cost less accumulated depreciation. Depreciation is computed primarily using the straight-line method over the estimated useful lives of the assets. Real estate was not adjusted to market value at the date of purchase.

Assets in the amount of \$809,417 and \$830,197 at December 31, 2023 and 2022, respectively, were on deposit with government authorities or trustees as required by law.

The Company participates in the Federal Employee Health Benefits Program ("FEHBP") with other Blue Cross Blue Shield Plans. This program includes a fully-insured experience-rated contract, commonly known as the FEP, between the OPM and BCBSA, which acts as an agent for the participating Blue Cross Blue Shield plans. In addition, each participating plan, including the Company, executes a contract with BCBSA which obligates each participating plan to underwrite FEP benefits in its service area.

FEP premium is earned when chargeable benefit costs, allowable expenses or retentions are incurred. Deferred premiums are recorded to offset the FEP liabilities for incurred claims but not reported and claims adjustment expenses that are due from the OPM, when the claims are ultimately paid. Premium rates are developed by BCBSA and negotiated with OPM annually. These rates determine the funds that will be available to the participating Blue Cross Blue Shield plans to provide insurance to Federal employees that enroll with the Blue Cross Blue Shield FEP. The excess of gross premiums for the life of the program over the charges for the life of the program on an accrual basis is accounted for as a rate stabilization reserve (commonly referred to as the special reserve), as required by the contract between OPM and BCBSA. Each year, OPM also allocates a portion of the premiums to a contingency reserve, which may be utilized by the participating plans in the event that annual premiums paid to the insurance carrier are insufficient or the rate stabilization reserve falls below certain levels prescribed by OPM. Premiums paid to the carrier and available to each participating Blue Cross Blue Shield plan, including the special reserve and the contingency reserve, are held at the U.S. Treasury, including amounts unused from prior periods. Any premiums that remain in the

rate stabilization reserve upon termination of the BCBSA contract after the claims runout and reimbursement of allowable administrative expenses would be returned to OPM for the benefit of the FEHBP. The FEP contract renews automatically each year unless written notice of termination is given by either party.

In accordance with the FEP contract, premium funds that exceed daily operating needs are held on behalf of the Company in letter of credit accounts at the U.S. Treasury to provide funding for claims, administrative expenses, and other charges to the contract. The Company, along with other Blue Cross Blue Shield plans who participate in the FEHBP contract, have an unrestricted right to draw funds being held in the U.S. Treasury, other than those allocated to the contingency reserve, for any valid claim or expense. If the balance of the special reserve is exhausted or falls below certain prescribed levels, OPM will transfer funds from the contingency reserve to the special reserve to the extent that funds are available in the contingency reserve. Amounts incurred in excess of the total reserves held at the U.S. Treasury for the FEP would not be reimbursed to the Company.

The Company has recorded its allocable share of the special reserve funds held in the U.S. Treasury as an asset, with an equivalent amount recorded as a rate stabilization reserve. These amounts are \$51,580,259 and \$55,438,580 as of December 31, 2023 and 2022, respectively, and are included in aggregate write-ins for other than invested assets and in health policy reserves in the accompanying balance sheets.

FEP represented approximately 61.5% and 54.9% of premiums receivable as of December 31, 2023 and 2022, respectively. FEP represented approximately 22.7% and 21.3% of net premiums written for the years ended December 31, 2023 and 2022, respectively.

D. Business Interruption Insurance Recoveries

The Company has reported no recoveries for business interruption for the years ended December 31, 2023 and 2022.

E. State Transferable and Non-Transferable Tax Credits

The Company did not have state transferable or non-transferable tax credits at December 31, 2023 and 2022.

F. Subprime Mortgage-Related Risk Exposure

- (1) The Company's investment strategy of providing safety and preservation of capital, sufficient liquidity to meet cash flow requirements and the attainment of a competitive after-tax investment return is supported by a well diversified portfolio consisting of many different types of investments. The portion of the Company's investment portfolio with subprime mortgage-related risk exposure is relatively small in comparison to the overall investment portfolio, and consists mainly of investment grade securities with no exposure to collateralized debt obligations. All mortgage related investments are monitored closely as part of the quarterly investment review performed by the Elevance Health Investment Impairment Review Committee.
- (2) The Company did not carry investments in subprime mortgage loans in its portfolio at December 31, 2023 or 2022.

(3) At December 31, 2023, the Company's subprime mortgage-related risk exposure is detailed below:

	A	Actual Cost	Book/ Adjusted Carrying Value (excluding interest)	Fair Value	Other-Than- Temporary Impairment Losses Recognized
a. Residential mortgage- backed securities	\$	1,515,431	\$ 1,510,758	\$ 1,402,746	\$
b. Commercial mortgage- backed securities		_			_
c. Collateralized debt obligations		_			_
d. Structured securities					
e. Equity investments in SCAs		_			_
f. Other assets		_		_	
g. Total	\$	1,515,431	\$ 1,510,758	\$ 1,402,746	\$

(4) The Company did not underwrite Mortgage Guaranty or Financial Guaranty insurance coverage at December 31, 2023 or 2022.

G. Retained Assets

The Company does not have retained assets at December 31, 2023 and 2022.

H. Insurance-Linked Securities Contracts

Not applicable.

I. The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy

Not applicable.

22. Events Subsequent

Subsequent events have been considered through February 28, 2024 for the statutory statement issued on February 29, 2024. There were no events occurring subsequent to December 31, 2023 requiring recognition or disclosure.

23. Reinsurance

A. Ceded Reinsurance Report

Section 1 - General Interrogatories

(1) Are any of the reinsurers that are listed in Schedule S as non-affiliated owned in excess of 10% or controlled, either directly or indirectly, by the Company or by any representative, officer, trustee, or director of the Company?

Yes () No (X)

If yes, give full details.

(2)	Have any policies issued by the Company been reinsured with a company chartered in
	a country other than the United States (excluding U.S. Branches of such companies)
	that is owned in excess of 10% or controlled, directly or indirectly, by an insured, a
	beneficiary, a creditor or an insured or any other person not primarily engaged in the
	insurance business?

Yes () No (X)

If yes, give full details.

Section 2 - Ceded Reinsurance Report - Part A

(1) Does the Company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credits?

Yes () No (X)

If yes, give full details.

(2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

Yes () No (X)

If yes, give full details.

Section 3 - Ceded Reinsurance Report - Part B

(1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the Company may consider the current or anticipated experience of the business reinsured in making this estimate.

(\$907)

(2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the Company as of the effective date of the agreement?

Yes () No (X)

If yes, give full details.

B. Uncollectible Reinsurance

The Company has no uncollectible reinsurance at December 31, 2023 and 2022.

C. Commutation of Ceded Reinsurance

The Company has not commuted ceded reinsurance during 2023 and 2022.

D. Certified Reinsurer Rating Downgraded or Status Subject Revocation

The Company has no downgraded certified reinsurer ratings or status subject to revocations during 2023 and 2022.

E. Reinsurance Credit

(1) The Company has the following reinsurance contracts subject to Life and Health Reinsurance Agreements Model Regulation Appendix A-791 ("A-791") that includes a provision which limits the reinsurer's assumption of risks, such as a deductible, a loss ratio corridor, a loss cap, or an aggregate limit, as defined in A-791:

Name of Reinsurer	Number of contracts to which such provisions apply	Was Deposit Accounting Applied (Yes or No)
Maine Guaranteed Access Reinsurance Association	1	No

- (2) Not applicable.
- (3) Not applicable.
- (4) Not applicable.
- (5) Not applicable.

24. Retrospectively Rated Contracts & Contracts Subject to Redetermination

- **A.** The Company sells accident and health policies for which the premiums vary based on loss experience. The Company estimates retrospective premium adjustments through the review of each retrospectively rated account, comparing the claim development with that anticipated in the policy contracts.
- **B.** The Company records accrued retrospective premium as an adjustment to earned premium.
- C. The amount of net premiums written by the Company at December 31, 2023 and 2022 that were subject to retrospective rating features was \$1,194,741,630 and \$1,120,363,138, respectively, which represented 98.0% and 92.8%, respectively, of the total net premiums written.
- D. In accordance with the NAIC SAP, medical loss ratio rebates in accordance with the Federal 2010 Patient Protection and Affordable Care Act and Public Health Service Act ("ACA Act" or "ACA"), are to be reported in accordance with SSAP No. 66 Retrospectively Rated Contracts ("SSAP No. 66"). A retrospectively rated contract is one that has the final policy premium calculated based on the loss experience of the insured during the term of the policy (including loss development after the term of the policy) and the stipulated formula set forth in the policy, or in the case of medical loss ratio rebates, a formula required by law. The Company based the incurred and unpaid liability amounts reported below based on its underwriting experience; actuarial, tax, and accounting estimates and assumptions at the financial statement date; as well as regulations and guidance available that is not final and subject to change prior to settlement. Accordingly, the Company's use of estimates and assumptions in the preparation of the statutory based financial statements and related footnote disclosures may differ from actual results. Hence, the amounts reported herein are for financial reporting purposes solely and not intended to be used for settlement purposes.

Medical loss ratio rebates accrued pursuant to the ACA Act are as follows:

	Individual	Small Group Employer	Large Group Employer	Other Categories with Rebates	Total
Prior Year Reporting:					
(1) Medical loss ratio rebates incurred	\$ 4,090,205	\$ (170,793)	\$ —	\$ —	\$ 3,919,412
(2) Medical loss ratio rebates paid	8,374,926	3,618,937	_	_	11,993,863
(3) Medical loss ratio rebates unpaid	3,536,682	_	_	_	3,536,682
(4) Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	_
(5) Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	_
(6) Rebates unpaid net of reinsurance	XXX	XXX	XXX	XXX	3,536,682
Current Reporting Year-to-Date					
(7) Medical loss ratio rebates incurred	\$ (161,200)	\$ 435,108	\$ —	\$ —	\$ 273,908
(8) Medical loss ratio rebates paid	2,975,482	435,108	_	_	3,410,590
(9) Medical loss ratio rebates unpaid	400,000	_	_	_	400,000
(10) Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	_
(11) Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	_
(12) Rebates unpaid net of reinsurance	XXX	XXX	XXX	XXX	\$ 400,000

E. Risk-Sharing Provisions of the ACA

(2)

	I the reporting entity write accident and health insurance premium that is subject to Affordable Care Act risk-sharing provisions (YES/NO)?	_	Yes
	pact of Risk-Sharing Provisions of the Affordable Care Act on Admitted Assets, bilities and Revenue for the Current Year		
a.	Permanent ACA Risk Adjustment Program		
	Assets		
	 Premium adjustments receivable due to ACA Risk Adjustment (including high risk pool payments) 	\$	102,463
	Liabilities		
	2. Risk adjustment user fees payable for ACA Risk Adjustment	\$	105,586
	3. Premium adjustments payable due to ACA Risk Adjustment (including high risk pool premiums)	\$	12,815,829
	Operations (Revenue & Expense)		
	4. Reported as revenue in premium for accident and health contracts (written/collected) due to ACA Risk Adjustment	\$	(9,949,326)
	5. Reported in expenses as ACA risk adjustment user fees (incurred/paid)	\$	106,382
b.	Transitional ACA Reinsurance Program		
	Assets		
	1. Amounts recoverable for claims paid due to ACA Reinsurance	\$	_
	2. Amounts recoverable for claims unpaid due to ACA Reinsurance (contra liability)	\$	_
	3. Amounts receivable relating to uninsured plans for contributions for ACA Reinsurance	\$	_
	Liabilities		
	4. Liabilities for contributions payable due to ACA Reinsurance - not reported as ceded premium	\$	_
	5. Ceded reinsurance premiums payable due to ACA Reinsurance	\$	_
	 Liability for amounts held under uninsured plans contributions for ACA Reinsurance 	\$	_
	Operations (Revenue & Expense)		
	7. Ceded reinsurance premiums due to ACA Reinsurance	\$	
	Reinsurance recoveries (income statement) due to ACA Reinsurance payments or expected payments	\$	
	9. ACA Reinsurance contributions - not reported as ceded premium	\$	
c.	Temporary ACA Risk Corridors Program		
	Assets		
	1. Accrued retrospective premium due to ACA Risk Corridors	\$	_
	Liabilities		
	Reserve for rate credits or policy experience rating refunds due to ACA Risk Corridors	\$	_
	Operations (Revenue & Expense)		
	3. Effect of ACA Risk Corridors on net premium income (paid/received)	\$	
	4. Effect of ACA Risk Corridors on change in reserves for rate credits	\$	

(3) Roll-forward of prior year ACA risk-sharing provisions for the following asset (gross of any nonadmission) and liability balances, along with the reasons for adjustments to prior year balance.

			Prior Year		the Curre	r Paid as of nt Year on	Differ	rences	Adj	justments		alances as of rting Date
			Written December 31 Ye			ritten Before I of the Prior ear	Prior Year Accrued Less Payments (Col 1-3)	Prior Year Accrued Less Payments (Col 2-4)	To Prior Year Balances	To Prior Year Balances	Cumulative Balance from Prior Years (Col 1-3+7)	Cumulative Balance from Prior Years (Col 2-4+8)
			1	2	3	4	5	6	7	8	9	10
			Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable) Re	f Receivable	(Payable)
a.	Adjı	nanent ACA Risk ustment Program										
	1.	Premium adjustments receivable (including high risk pool payments)	\$ 2,376,747	s –	\$ 7,606,775	s –	\$(5,230,028)	s –	\$ 5,230,028	\$ <u> </u>	s —	s <u> </u>
	2.	Premium adjustments (payable) (including high risk pool premiums)	s –	\$13,432,070	s –	\$14,833,523	s –	\$(1,401,453)	s –	\$ 1,401,453 B	s –	s <u> </u>
	3.	Subtotal ACA Permanent Risk Adjustment Program	\$ 2,376,747	\$13,432,070	\$ 7,606,775	\$14,833,523	\$(5,230,028)	\$(1,401,453)	\$ 5,230,028	\$ 1,401,453	s –	s –
b.		nsitional ACA Reinsurance gram										
	1.	Amounts recoverable for claims paid	s –	s –	s –	s –	s –	s –	s –	s — C	s –	s –
	2.	Amounts recoverable for claims unpaid (contra liability)	s –	s –		s –	s –	s –	s –	\$ — D		s –
	3.	Amounts receivable relating to uninsured plans	s –	s –	s –	s –	s –	s –	s –	\$ — E		s –
	4.	Liabilities for	<u>s</u> —	3 —	3 —	3 —	3 —	3 —	3 —	<u> </u>	<u> </u>	<u>s — </u>
		contributions payable due to ACA Reinsurance - not reported as ceded premium	s —	s —	s —	s —	s —	s —	s —	\$ — F	s —	s —
	5.	Ceded reinsurance premiums payable	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
	,	I inhiliter for a survey hald	<u> </u>	s —	s <u> </u>	s —	s <u> </u>	s <u> </u>	s <u> </u>	\$ <u> </u>	<u>\$</u>	<u> </u>
	6.	Liability for amounts held under uninsured plans	s –	s –	s –	s –	s –	s –	s –	\$ — H	s —	s —
	7.	Subtotal ACA Transitional Reinsurance Program	s –	s –	s –	s –	s –	s –	s –	s –	s –	s –
c.		nporary ACA Risk ridors Program		<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>		<u> </u>	
	1.	Accrued retrospective premium	s –	s –	s –	s –	s –	s –	s –	\$ — I	s –	s –
	2.	Reserve for rate credits or policy experience rating refunds	s –	s –	s –			s –	s –	\$ _ J	s —	s —
	3.	Subtotal ACA Risk Corridors Program					-	-				
d.	Tota	al for ACA Risk Sharing	<u> </u>	<u>\$</u>	<u> </u>	<u>\$</u>	<u> </u>	<u>\$</u>	\$ <u> </u>	<u>s</u> —	<u> </u>	<u> </u>
u.		isions	\$ 2,376,747	\$13,432,070	\$ 7,606,775	\$14,833,523	\$(5,230,028)	\$(1,401,453)	\$ 5,230,028	\$ 1,401,453	<u> </u>	<u> </u>

Explanations of Adjustments

- A Adjustments were made to reflect the ending balance in the Centers for Medicare & Medicaid Services "Summary Report on Permanent Risk Adjustment Transfers for the 2022 Benefit Year."
- B Adjustments were made to reflect the ending balance in the Centers for Medicare & Medicaid Services "Summary Report on Permanent Risk Adjustment Transfers for the 2022 Benefit Year."
- C Not applicable.
- D Not applicable.
- E Not applicable.
- F Not applicable.
- G Not applicable
- H Not applicable.
- I Not applicable.J Not applicable.
- (4) Roll-forward of Risk Corridors Asset and Liability Balances by Program Benefit Not applicable.
- (5) ACA Risk Corridors Receivable as of Reporting Date Not applicable.

25. Change in Incurred Claims and Claim Adjustment Expenses

- **A.** The estimated cost of claims and claim adjustment expense attributable to insured events of prior years decreased by \$18,086,366 during 2023. This is approximately 11.1% of unpaid claims and claim adjustment expenses, net of healthcare receivables, of \$163,421,785 as of December 31, 2022. The redundancy reflects the decreases in estimated claims and claims adjustment expenses as a result of claims payment during the year, and as additional information is received regarding claims incurred prior to 2023. Recent claim development trends are also taken into account in evaluating the overall adequacy of unpaid claims and unpaid claim adjustment expense.
- **B.** There were no significant changes in methodologies and assumptions used in calculating the liability for unpaid losses and loss adjustment expenses.

26. Intercompany Pooling Arrangements

Not applicable at December 31, 2023 and 2022.

27. Structured Settlements

Not applicable at December 31, 2023 and 2022.

28. Health Care Receivables

A. Pharmaceutical Rebate Receivables

Quarter	Estimated Pharmacy Rebates as Reported on Financial Statements	Pharmacy Rebates as Billed or Otherwise Confirmed	Actual Rebates Received Within 90 Days of Billing	Actual Rebates Received Within 91 to 180 Days of Billing	Actual Rebates Received More Than 180 Days After Billing
12/31/2023	\$ 6,973,103	\$ 18,095,868	\$ 11,122,765	\$ —	\$ —
9/30/2023	6,853,506	18,389,070	17,315,119		
6/30/2023	6,424,656	16,835,952	15,859,593	976,358	
3/31/2023	6,354,349	15,591,917	14,240,920	1,350,997	_
12/31/2022	6,412,710	15,164,704	13,639,403	1,525,301	_
9/30/2022	5,680,222	14,471,827	13,243,187	1,228,640	_
6/30/2022	5,520,503	14,738,163	13,341,188	1,396,975	_
3/31/2022	6,101,461	13,712,502	12,487,769	1,224,733	_
12/31/2021	4,847,291	12,559,751	11,579,479	980,272	
9/30/2021	4,658,006	11,930,081	10,740,071	1,190,010	_
6/30/2021	4,498,943	8,267,932	7,661,773	606,159	_
3/31/2021	5,786,448	12,447,077	11,395,030	1,052,047	_

Note: Amounts within column "Estimated pharmacy rebates as reported on financial statements" include \$518,551 of uninsured admitted pharmacy rebate receivables at December 31, 2023 that are reported within Pg 2, Ln 17 "Amounts receivable relating to uninsured plans."

B. Risk Sharing Receivables

Not applicable at December 31, 2023 and 2022.

29. Participating Policies

Not applicable at December 31, 2023 and 2022.

30. Premium Deficiency Reserves

The Company had no liabilities related to premium deficiency reserves as of December 31, 2023 and 2022.

31. Anticipated Salvage and Subrogation

The Company took into account estimated anticipated subrogation and other recoveries in its determination of the liability for unpaid claims and reduced the liability by \$322,000 and \$1,029,000 at December 31, 2023 and 2022, respectively.

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES GENERAL

1.1	Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of which is an insurer? If yes, complete Schedule Y, Parts 1, 1A, 2 and 3.		Yes [X] No []
1.2	If yes, did the reporting entity register and file with its domiciliary State Insurance Commissioner, Director or Superintendent or with such regulatory official of the state of domicile of the principal insurer in the Holding Company System, a registration statement providing disclosure substantially similar to the standards adopted by the National Association of Insurance Commissioners (NAIC) in its Model Insurance Holding Company System Regulatory Act and model regulations pertaining thereto, or is the reporting entity subject to standards and disclosure requirements substantially similar to those required by such Act and regulations?	es [X] No [] N/A [1
1.3	State Regulating?		Maii	ne	
1.4	Is the reporting entity publicly traded or a member of a publicly traded group?		Yes [X] No []
1.5	If the response to 1.4 is yes, provide the CIK (Central Index Key) code issued by the SEC for the entity/group		000115	6039	
2.1	Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settlement of the reporting entity?		Yes [] No [X]
2.2	If yes, date of change:				
3.1	State as of what date the latest financial examination of the reporting entity was made or is being made.		12/31/	2022	
3.2	State the as of date that the latest financial examination report became available from either the state of domicile or the reporting entity. This date should be the date of the examined balance sheet and not the date the report was completed or released		12/31/	2017	
3.3	State as of what date the latest financial examination report became available to other states or the public from either the state of domicile or the reporting entity. This is the release date or completion date of the examination report and not the date of the examination (balance sheet date).		10/23/	2019	
3.4	By what department or departments? State of Maine Bureau of Insurance				
3.5	Have all financial statement adjustments within the latest financial examination report been accounted for in a subsequent financial statement filed with Departments?	s [] No [] N/A [Х]
3.6	Have all of the recommendations within the latest financial examination report been complied with?	s [] No [] N/A [Х]
4.1	During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organization or any combination thereof under common control (other than salaried employees of the reporting entity), receive credit or commissions for or cont a substantial part (more than 20 percent of any major line of business measured on direct premiums) of: 4.11 sales of new business?] No [X	
4.2	4.12 renewals?		res [] No [X	J
	4.21 sales of new business?] No [X] No [X	
5.1	Has the reporting entity been a party to a merger or consolidation during the period covered by this statement?		Yes [] No [X]
5.2	If yes, provide the name of the entity, NAIC Company Code, and state of domicile (use two letter state abbreviation) for any entity that has ceased to exist as a result of the merger or consolidation.				
	1 2 3 Name of Entity NAIC Company Code State of Domicile				
6.1	Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended revoked by any governmental entity during the reporting period?		Yes [] No [X]
6.2	If yes, give full information:				
7.1	Does any foreign (non-United States) person or entity directly or indirectly control 10% or more of the reporting entity?		Yes [] No [X]
7.2	If yes, 7.21 State the percentage of foreign control;				%
	1 2 Type of Entity				

8.1 8.2	Is the company a subsidiary of a depository institution holding compan If the response to 8.1 is yes, please identify the name of the DIHC.					Yes []	No [(]
8.3 8.4	Is the company affiliated with one or more banks, thrifts or securities fill fresponse to 8.3 is yes, please provide below the names and location regulatory services agency [i.e. the Federal Reserve Board (FRB), the Insurance Corporation (FDIC) and the Securities Exchange Commission	city and state of the main office) of any affiliates re Office of the Comptroller of the Currency (OCC), the	egulated b	y a fed	leral	Yes []	No [X]
	1 Affiliate Name	2 Location (City, State)	3 FRB (4 OCC	5 FDIC	6 SEC	;		
8.5	Is the reporting entity a depository institution holding company with significant Reserve System or a subsidiary of the depository institution holding company with significant reporting the state of t					Yes [1	No []	X]
8.6	If response to 8.5 is no, is the reporting entity a company or subsidiary Federal Reserve Board's capital rule?	of a company that has otherwise been made subje	ct to the	Ү] No [X]	N/A	[]
9.	What is the name and address of the independent certified public according to the Ernst & Young LLP, 111 Monument Circle, Suite 4000, Indianapolis, IN								
10.1	Has the insurer been granted any exemptions to the prohibited non-au requirements as allowed in Section 7H of the Annual Financial Reportillaw or regulation?	dit services provided by the certified independent p ing Model Regulation (Model Audit Rule), or substar	ublic acco ntially simi	untant ilar sta	te	Yes []	No [Х]
10.2	If the response to 10.1 is yes, provide information related to this exemp								
	Has the insurer been granted any exemptions related to the other requallowed for in Section 18A of the Model Regulation, or substantially sin	uirements of the Annual Financial Reporting Model Financial Reporting Financial Reporting Model Financial Reporting Financial Financial Reporting Financial Reporting Financial Financial Reporting Financial Financial Financial Financial Financial Financia	Regulation	n as		Yes []	No [Х]
10.4	If the response to 10.3 is yes, provide information related to this exemp								
10.5 10.6	Has the reporting entity established an Audit Committee in compliance If the response to 10.5 is no or n/a, please explain.	with the domiciliary state insurance laws?		Ү	es [X	.] No []	N/A	[]
11.	What is the name, address and affiliation (officer/employee of the repo- firm) of the individual providing the statement of actuarial opinion/certif Christine Valdez, FSA, MAAA, Director & Actuary III (employee), 2045.	orting entity or actuary/consultant associated with an fication?	n actuarial	consul	Iting				
12.1		·				Yes [1	No []	X 1
		estate holding company					•		•
	•	rcels involved							
12.2	12.13 Total book/adj	usted carrying value				.\$			
12.2	ii yes, provide explanation								
13.	FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITI	ES ONLY:							
13.1	What changes have been made during the year in the United States m	· ·							
13.2	Does this statement contain all business transacted for the reporting e	, ,				Yes []	No []
13.3						Yes []	No []
13.4	If answer to (13.3) is yes, has the domiciliary or entry state approved the Are the senior officers (principal executive officer, principal financial of] No [.]	N/A	[]
14.1	similar functions) of the reporting entity subject to a code of ethics, whi a. Honest and ethical conduct, including the ethical handling of actual relationships:	ich includes the following standards?				Yes [Х]	No []
	b. Full, fair, accurate, timely and understandable disclosure in the period. Compliance with applicable governmental laws, rules and regulation	ns;	ity;						
	d. The prompt internal reporting of violations to an appropriate person	or persons identified in the code; and							
14.11	e. Accountability for adherence to the code. If the response to 14.1 is No, please explain:								
	Has the code of ethics for senior managers been amended?					Yes []	No [Х]
14.21	If the response to 14.2 is yes, provide information related to amendme								
	Have any provisions of the code of ethics been waived for any of the sift the response to 14.3 is yes, provide the nature of any waiver(s).	pecified officers?				Yes []	No []	Κ]

1	2		3		4	
Ameri Bank Associ	ers ation					
(ABA) R Num		Circumstances	That Can Trigger the Letter of Credit	An	noun	ıt
	rchase or sale of all investments of the reporting entity passed		of directors or a subordinate committee	Yes [X	(]	No [
Does the	e reporting entity keep a complete permanent record of the pro	oceedings of its board of dir	ectors and all subordinate committees	Yes [X		
Has the part of ar	reporting entity an established procedure for disclosure to its I ny of its officers, directors, trustees or responsible employees	board of directors or trustee that is in conflict or is likely	s of any material interest or affiliation on the to conflict with the official duties of such	Yes [X	(]	No [
persons				103 [//	,]	INO [
		FINANCIAL				
Has this	statement been prepared using a basis of accounting other tring Principles)?	nan Statutory Accounting Pr	inciples (e.g., Generally Accepted	Yes [1	Nο
Total am	ount loaned during the year (inclusive of Separate Accounts,	exclusive of policy loans):	20.11 To directors or other officers	\$		
			20.12 To stockholders not officers	\$		
			20.13 Trustees, supreme or grand (Fraternal Only)	œ		
Total am	ount of loans outstanding at the end of year (inclusive of Sepa	arate Accounts, exclusive o	f , , , , , , , , , , , , , , , , , , ,			
policy loa			20.21 To directors or other officers			
			20.22 To stockholders not officers	•		
Were an	y assets reported in this statement subject to a contractual ob n being reported in the statement?	ligation to transfer to anoth	er party without the liability for such			
If yes, sta	ate the amount thereof at December 31 of the current year:		21.21 Rented from others			
			21.22 Borrowed from others			
			21.23 Leased from others			
D 41-1-		:- th A Ot-t t l	21.24 Other	\$		
quaranty	s statement include payments for assessments as described in assessments?	in the Annual Statement ins	uructions other than guaranty fund of	Yes [)	(]	No
If answer			2.21 Amount paid as losses or risk adjustmen			
			2.22 Amount paid as expenses			
		22	2.23 Other amounts paid	\$		7,
	e reporting entity report any amounts due from parent, subsidia	_		-	-	
Does the	dicate any amounts receivable from parent included in the Pares insurer utilize third parties to pay agent commissions in whic	h the amounts advanced by	the third parties are not settled in full within	\$ Yes [
	ponse to 24.1 is yes, identify the third-party that pays the age			.00 [,	
		Is the				
	Name of Third-Party	Third-Party Age a Related Par (Yes/No)				
	Name of Tillian arty	(163/140)				

25.02	22 If no, give full and complete information, relating thereto					
25.03	For securities lending programs, provide a description of the program including value for collateral and am whether collateral is carried on or off-balance sheet. (an alternative is to reference Note 17 where this info See Notes 5E and 17.	ormation is also provided)				
25.04	For the reporting entity's securities lending program, report amount of collateral for conforming programs a Instructions.	as outlined in the Risk-Based Capital	.\$		10,4	441,96
25.05	For the reporting entity's securities lending program, report amount of collateral for other programs		\$			
25.06	Does your securities lending program require 102% (domestic securities) and 105% (foreign securities) fro outset of the contract?		X] No) [] N/	/A [
25.07	Does the reporting entity non-admit when the collateral received from the counterparty falls below 100%?	Yes [X] No	, [] N/	/A [
25.08	Does the reporting entity or the reporting entity's securities lending agent utilize the Master Securities lend conduct securities lending?		X] No) [] N/	/A [
25.09	99 For the reporting entity's securities lending program state the amount of the following as of December 31 of	of the current year:				
	 25.091 Total fair value of reinvested collateral assets reported on Schedule DL, Parts 1 a 25.092 Total book/adjusted carrying value of reinvested collateral assets reported on Sch 25.093 Total payable for securities lending reported on the liability page 	nedule DL, Parts 1 and 2	\$		10,4	441,96
26.1	Were any of the stocks, bonds or other assets of the reporting entity owned at December 31 of the current control of the reporting entity or has the reporting entity sold or transferred any assets subject to a put opt force? (Exclude securities subject to Interrogatory 21.1 and 25.03).	tion contract that is currently in	Yes	[X]	No	[]
26.2	26.22 Subject to reve 26.23 Subject to dolla 26.24 Subject to reve 26.25 Placed under o	urchase agreements	.\$ \$ \$			
	26.27 FHLB Capital S 26.28 On deposit with 26.29 On deposit with 26.30 Pledged as col an FHLB	securities restricted as to sale - B Capital Stock Stock h states h other regulatory bodies llateral - excluding collateral pledged to	\$ \$ \$ \$			809,41
26.3	Nature of Restriction Desc	2 cription		3 Amou		
26.3	1 Nature of Restriction Desc			Amou		
26.327.1	Nature of Restriction Desc	cription		Amou		
	1 Nature of Restriction Description 1 Does the reporting entity have any hedging transactions reported on Schedule DB?	cription	Yes	<u>Amou</u>	l No	
27.1 27.2	1 Nature of Restriction Description 1 Does the reporting entity have any hedging transactions reported on Schedule DB?	cription	Yes	<u>Amou</u>	l No	
27.1 27.2	1 Nature of Restriction Desc 1 Does the reporting entity have any hedging transactions reported on Schedule DB? 2 If yes, has a comprehensive description of the hedging program been made available to the domiciliary stalf no, attach a description with this statement. 3 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY:	ate? Yes [Yes	Amou 	l No	 [X] /A [
27.1 27.2 INES 2	1 Nature of Restriction Description Description gentity have any hedging transactions reported on Schedule DB? If yes, has a comprehensive description of the hedging program been made available to the domiciliary stall fino, attach a description with this statement. S 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as	ate? Yes [s a result of interest rate sensitivity?	Yes] No	() [] [] []	No N	[X] /A [
27.1 27.2 INES 2 27.3	1 Does the reporting entity have any hedging transactions reported on Schedule DB?	ate?	Yes] No Yes Yes	[] [] []	No N	[X] /A [[] [] []
27.1 27.2 INES 2 27.3 27.4	Nature of Restriction Description Description of the hedging program been made available to the domiciliary statistic of the reporting entity have any hedging transactions reported on Schedule DB? If yes, has a comprehensive description of the hedging program been made available to the domiciliary statistic of the description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as lift the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special accounting provision of SSAP 27.42 Permitted accounting practice	ate? Yes [s a result of interest rate sensitivity? No. 108	Yes] No Yes Yes Yes Yes Yes	[] [] []	No No No No No No No	[X] /A [[] [] []
27.1 27.2 INES 2 27.3 27.4	1 Does the reporting entity have any hedging transactions reported on Schedule DB?	ate? Yes [s a result of interest rate sensitivity? No. 108 porting entity attests to the of VM-21. It within the establishment of VM-21 hal Tail Expectation Amount. the definition of a Clearly Defined hetegy being used by the company in entito equity, or, at the option of the	Yes J No Yes Yes Yes Yes Yes	Amou [] [] [] [] []	No N	
27.1 27.2 INES 2 27.3 27.4 27.5	1 Does the reporting entity have any hedging transactions reported on Schedule DB?	ate? Yes [No. 108 Yes I within the establishment of VM-21 all Tail Expectation Amount. The definition of a Clearly Defined ategy being used by the company in the into equity, or, at the option of the eld physically in the reporting entity's current year held pursuant to a amination Considerations, F.	Yes] No Yes Yes Yes Yes Yes Yes	[] [] [] []	No N	
27.1 27.2 INES 2 27.3 27.4 27.5	Nature of Restriction Desc. Nature of Restriction If yes, has a comprehensive description of the hedging program been made available to the domiciliary start of the notion of the hedging program been made available to the domiciliary start of the notion of the hedging program been made available to the domiciliary start of the response to 27.5 FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as If the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special accounting provision of SSAP 27.42 Permitted accounting practice 27.43 Other accounting guidance 27.43 Other accounting guidance 27.43 Other accounting guidance 27.43 Other accounting provisions of SSAP No. 108, the restriction of the reporting entity has obtained explicit approval from the domiciliary state. Hedging strategy subject to the special accounting provisions is consistent with the requirements Actuarial certification has been obtained which indicates that the hedging strategy is incorporated reserves and provides the impact of the hedging strategy within the Actuarial Guideline Condition Financial Officer Certification has been obtained which indicates that the hedging strategy meets Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy is the hedging strate is actual day-to-day risk mitigation efforts. Were any preferred stocks or bonds owned as of December 31 of the current year mandatorily convertible issuer, convertible into equity? If yes, state the amount thereof at December 31 of the current year. Excluding items in Schedule E - Part 3 - Special Deposits, real estate, mortgage loans and investments he offices, vaults or safety deposit boxes, were all stocks, bonds and other securities, owned throughout the custodial	ate? Yes [The sa result of interest rate sensitivity? The No. 108 The porting entity attests to the sensitivity and the sensitivity attests to the sensitivity attests to the sensitivity attests to the sensitivity attests to the sensitivity and the sensitivity attests to the sensitivity attests to the sensitivity. The sensitivity attests to the sensitivity attests to the sensitivity attests to the sensitivity and the sensitivity attests to the sensitivity. The sensitivity attests to the sensitivity attention attenti	Yes] No Yes Yes Yes Yes Yes Yes	[] [] [] []	No N	
27.1 27.2 INES 2 27.3 27.4 27.5	1 Does the reporting entity have any hedging transactions reported on Schedule DB?	ate? Yes [s a result of interest rate sensitivity? No. 108 porting entity attests to the of VM-21. It within the establishment of VM-21 hal Tail Expectation Amount. the definition of a Clearly Defined lategy being used by the company in e into equity, or, at the option of the eld physically in the reporting entity's current year held pursuant to a amination Considerations, F. Examiners Handbook? complete the following:	Yes] No Yes Yes Yes Yes Yes Yes	Amou [] [] [] [] []	No N	[X] [X] [] [] [X]

GENERAL INTERROGATORIES

29.02	For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location
	and a complete explanation:

1	2	3
Name(s)	Location(s)	Complete Explanation(s)

29.03	Have there been any changes, including name changes, in the custodian(s) identified in 29.01 during the current year?	Yes []	No	[X]
29.04	If yes, give full and complete information relating thereto:				

1	2	3	4
Old Custodian	New Custodian	Date of Change	Reason

29.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. For assets that are managed internally by employees of the reporting entity, note as such. ["...that have access to the investment accounts"; "...handle securities"]

1	2
Name of Firm or Individual	Affiliation
Elevance Health, Inc.	1
Loomis, Sayles & Company, LP	U
Pacific Investment Management Company	
, ,	

29.0597 For those firms/individuals listed in the table for Question 29.05, do any firms/individuals unaffiliated with the reporting entity (i.e.	
designated with a "III") manage more than 10% of the reporting entity's invested assets?	loN [X] saY

29.06 For those firms or individuals listed in the table for 29.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for the table below.

1	2	3	4	5
				Investment
				Management
Central Registration				Agreement
Depository Number	Name of Firm or Individual	Legal Entity Identifier (LEI)	Registered With	(IMA) Filed
			Securities Exchange	
105377	Loomis, Sayles & Company, LP	JIZPN2RX3UMN0YIDI313	Commission	NO
			Securities Exchange	
104559	Pacific Investment Management Company		Commission	NO

30.1	Does the reporting entity have any diversified mutual funds reported in Schedule D, Part 2 (diversified according to the Securities and					
	Exchange Commission (SEC) in the Investment Company Act of 1940 [Section 5(b)(1)])?	Yes []	No	, [X	(]

30.2 If yes, complete the following schedule:

1	2	3
		Book/Adjusted
CUSIP#	Name of Mutual Fund	Carrying Value
30.2999 - Total		0

30.3 For each mutual fund listed in the table above, complete the following schedule:

1	2	3	4
		Amount of Mutual	
		Fund's Book/Adjusted	
		Carrying Value	
	Name of Significant Holding of the	Attributable to the	Date of
Name of Mutual Fund (from above table)	Mutual Fund	Holding	Valuation

GENERAL INTERROGATORIES

31. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1	2	3
			Excess of Statement
			over Fair Value (-), or
	Statement (Admitted)		Fair Value over
	Value	Fair Value	Statement (+)
31.1 Bonds	296,631,138	278 , 132 , 797	(18,498,341)
31.2 Preferred stocks	0		0
31.3 Totals	296,631,138	278, 132, 797	(18,498,341)

31.4	Describe the sources or methods utilized in determining the fair values:			
	Fair values were obtained from third-party pricing sources. If a security was not priced by a third-party pricing source, internal analytical systems or broker quotes were utilized.			
32.1	Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D?	Yes []	No [X]
32.2	If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source?	Yes []	No []
32.3	If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:			
33.1 33.2	Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed?	Yes [Х]	No []
34.	By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security: a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available. b. Issuer or obligor is current on all contracted interest and principal payments. c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal.			
	Has the reporting entity self-designated 5GI securities?	Yes []	No [X]
35.	By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security: a. The security was purchased prior to January 1, 2018. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators. d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO.			
	Has the reporting entity self-designated PLGI securities?	Yes []	No [X]
36.	By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund: a. The shares were purchased prior to January 1, 2019. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019. d. The fund only or predominantly holds bonds in its portfolio. e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO. f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed.			
	Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria?	Yes []	No [X]
37.	By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following: a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date. b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties. c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review. d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 37.a - 37.c are reported as long-term investments.	1. No. 1	· v 1	N/A I
	Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria?	1 110	. ^]	IN/A [

3.1 Does the reporting entity directly hold cryptocurrencies?			Yes [] No [X]]
If the response to 38.1 is yes, on what schedule are they reported?				
Does the reporting entity directly or indirectly accept cryptocurrencies as payments for premiums on policies?			Yes [] No [X]]
39.2 If the response to 39.1 is yes, are the cryptocurrencies held directly or are they immediately converted to U.S. dollars? 39.21 Held directly]
			ies [] No []	ı
1 Name of Cryptocurrency	Converted to ÚSD, Property Held, or Both Property Held, or Both			
			<u></u>	
			\$ 213,4	460
		ents to trade associatio	ns,	
1 Nome		2		
Blue Cross Blue Shield Association	213,460			
Amount of payments for legal expenses, if any?			\$	102
List the name of the firm and the amount paid if any such payment represented 28 during the period covered by this statement.	5% or more of the total payments for I	egal expenses		
1 Name				
Amount of payments for expenditures in connection with matters before legislative	e bodies, officers or departments of go	overnment, if any?	\$	697
1 Name	Δmc	2 ount Paid		
Preti Flaherty Beliveau Pachios LLP		52,540		
	If the response to 38.1 is yes, on what schedule are they reported? Does the reporting entity directly or indirectly accept cryptocurrencies as payment if the response to 39.1 is yes, are the cryptocurrencies held directly or are they in 39.21 Held directly 39.22 Immediately or 39.22 Immediately or 39.21 immediately or 39.22 Immediately or 39.21 is yes, list all cryptocurrencies accepted for payment of Cryptocurrency OTH Amount of payments to trade associations, service organizations and statistical or List the name of the organization and the amount paid if any such payment represervice organizations and statistical or rating bureaus during the period covered by Name Blue Cross Blue Shield Association Amount of payments for legal expenses, if any? List the name of the firm and the amount paid if any such payment represented 2 during the period covered by this statement. 1	If the response to 38.1 is yes, on what schedule are they reported? Does the reporting entity directly or indirectly accept cryptocurrencies as payments for premiums on policies?	If the response to 38.1 is yes, on what schedule are they reported? Consider the reporting entity directly or indirectly accept cryptocurrencies as payments for premiums on policies? Consider the response to 39.1 is yes, are the cryptocurrencies held directly or are they immediately converted to U.S. dollars? 39.21 held directly 39.22 lmmediately converted to U.S. dollars Converte	Does the reporting entity directly or indirectly accept cryptocurrencies as payments for premiums on policies? Does the reporting entity directly or indirectly accept cryptocurrencies as payments for premiums on policies? 39 21 Held directly

Lobbying expenses disclosed reflect amounts reported in the Lobbyist Disclosure Reports filed with the Secretary of State as well as the cost of external contractors who provided lobbying services to the Company. The amount may include expenses that may have been paid by an affiliate on behalf of the Company and, as a result, may not be included in the Underwriting Gain reported on page 4 of the 2023 Annual Statement.

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

it yes, indicate premium earned on U.S. business only	n force?	
What portion of Item (1.2) is not reported on the Medicare Supplement Insu 1.31 Reason for excluding		
Indicate amount of earned premium attributable to Canadian and/or Other A	Alien not included in Item (1.2) above	.\$
Indicate total incurred claims on all Medicare Supplement Insurance		
Individual policies:	Most current three years:	•
	1.61 Total premium earned	s 14 493 1
	1.62 Total incurred claims	
	1.63 Number of covered lives	
	All years prior to most current three years:	
	1.64 Total premium earned	
	1.65 Total incurred claims	
	1.66 Number of covered lives	15,6
Group policies:	Most current three years:	
	1.71 Total premium earned	\$
	1.72 Total incurred claims	\$
	1.73 Number of covered lives	
	All years prior to most current three years:	
	1.74 Total premium earned	¢
	1.75 Total incurred claims	
	1.76 Number of covered lives	
Health Test:		
	1 2 Current Year Prior Year	
2.1 Premium Numerator		
2.2 Premium Denominator		
2.3 Premium Ratio (2.1/2.2)		
2.4 Reserve Numerator		
2.5 Reserve Denominator		
2.6 Reserve Ratio (2.4/2.5)		
Have copies of all agreements stating the period and nature of hospitals', pi		
dependents been filed with the appropriate regulatory agency?		Yes [X] No []
If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do	•	Yes [] No []
Does the reporting entity have stop-loss reinsurance?		Yes [] No [X]
If no, explain:		ies [] NO [x]
Elevance Health, Inc. has financial reserves available to cover catastrophic	losses. Also see the response to question 6 below	ies [] no [x]
•	c losses. Also see the response to question 6 below	
Elevance Health, Inc. has financial reserves available to cover catastrophic	5.31 Comprehensive Medical	\$
Elevance Health, Inc. has financial reserves available to cover catastrophic	5.31 Comprehensive Medical5.32 Medical Only	\$ \$
Elevance Health, Inc. has financial reserves available to cover catastrophic	5.31 Comprehensive Medical 5.32 Medical Only 5.33 Medicare Supplement	\$ \$ \$
Elevance Health, Inc. has financial reserves available to cover catastrophic	5.31 Comprehensive Medical	\$ \$ \$ \$
Elevance Health, Inc. has financial reserves available to cover catastrophic	5.31 Comprehensive Medical	\$ \$ \$ \$
Elevance Health, Inc. has financial reserves available to cover catastrophic Maximum retained risk (see instructions) Describe arrangement which the reporting entity may have to protect subschold harmless provisions, conversion privileges with other carriers, agreements	5.31 Comprehensive Medical	\$ \$ \$ \$
Elevance Health, Inc. has financial reserves available to cover catastrophic Maximum retained risk (see instructions) Describe arrangement which the reporting entity may have to protect subschold harmless provisions, conversion privileges with other carriers, agreements	5.31 Comprehensive Medical	\$ \$ \$ \$
Elevance Health, Inc. has financial reserves available to cover catastrophic Maximum retained risk (see instructions) Describe arrangement which the reporting entity may have to protect subschold harmless provisions, conversion privileges with other carriers, agreements: If the company becomes insolvent, Elevance Health, Inc. had agreed to the obligations of the Company. Effective November 30, 2018, the Company te Companies, Inc. The majority of provider and professional contracts include	5.31 Comprehensive Medical	\$sssssssss
Elevance Health, Inc. has financial reserves available to cover catastrophic Maximum retained risk (see instructions) Describe arrangement which the reporting entity may have to protect subschold harmless provisions, conversion privileges with other carriers, agreements: If the company becomes insolvent, Elevance Health, Inc. had agreed to the obligations of the Company. Effective November 30, 2018, the Company te Companies, Inc. The majority of provider and professional contracts include	5.31 Comprehensive Medical	\$sssssssss
Elevance Health, Inc. has financial reserves available to cover catastrophic Maximum retained risk (see instructions) Describe arrangement which the reporting entity may have to protect subschold harmless provisions, conversion privileges with other carriers, agreemagreements: If the company becomes insolvent, Elevance Health, Inc. had agreed to the obligations of the Company. Effective November 30, 2018, the Company te Companies, Inc. The majority of provider and professional contracts included to the reporting entity set up its claim liability for provider services on a second contract of the company.	5.31 Comprehensive Medical	\$
Elevance Health, Inc. has financial reserves available to cover catastrophic Maximum retained risk (see instructions) Describe arrangement which the reporting entity may have to protect subschold harmless provisions, conversion privileges with other carriers, agreemagreements: If the company becomes insolvent, Elevance Health, Inc. had agreed to the obligations of the Company. Effective November 30, 2018, the Company te Companies, Inc. The majority of provider and professional contracts include Does the reporting entity set up its claim liability for provider services on a self no, give details	5.31 Comprehensive Medical	\$

GENERAL INTERROGATORIES

10.1	Does the reporting entity have Incentive Pool, Withhold or Bonus Arrangements in its provider contracts?							No []
10.2	0.2 If yes: 10.21 Maximum amount payable bonuses. 10.22 Amount actually paid for year bonuse 10.23 Maximum amount payable withholds 10.24 Amount actually paid for year withhold						\$	6,991,531
11.1	Is the reporting entity organized as:			11.13 An Indivi	al Group/Staff Mode dual Practice Asso Model (combinatio	ciation (IPA), or,	Yes [] Yes [] Yes []	
11.2 11.3 11.4	Is the reporting entity subject to Statutory Minimum (If yes, show the name of the state requiring such min If yes, show the amount required.	nimum capital a	nd surplus					No [] <u>Maine</u> 64,914,968
11.5 11.6	Is this amount included as part of a contingency reself the amount is calculated, show the calculation 250% of Health Risk-Based Capital Authorized Cont							No [X]
12.	List service areas in which reporting entity is license	d to operate:						
				e Area				
13.1	Do you act as a custodian for health savings accoun	nts?					Yes []	No [X]
13.2	If yes, please provide the amount of custodial funds	held as of the re	eporting date				\$	
13.3	Do you act as an administrator for health savings ac	counts?					Yes []	No [X]
13.4	If yes, please provide the balance of funds administe	ered as of the re	porting date				\$	
14.1 14.2	Are any of the captive affiliates reported on Schedule If the answer to 14.1 is yes, please provide the follow		orized reinsurers?			Yes [] No [X] N/A []
	1	2	3	4		Supporting Reserv		
	Company Name	NAIC Company Code	Domiciliary Jurisdiction	Reserve Credit	5 Letters of Credit	6 Trust Agreements	7 Other	
15.	Provide the following for individual ordinary life insur ceded):	rance* policies (I	J.S. business only	15.1 E 15.2 T	ar (prior to reinsura Direct Premium Wr Total Incurred Clain	ince assumed or	\$	
		*Ordii	nary Life Insurance	Includes		_		
	Term(whether full und	derwriting, limite	d underwriting, jet	issue, "short form a				
	Whole Life (whether f			ig, jet issue, "short	torm app")	_		
	Universal Life (with or	r without second	ary gurarantee)					
	Variable Universal Life	e (with or withou	it secondary gurara	antee)				
16.	Is the reporting entity licensed or chartered, registered	ed, qualified, eliç	gible or writing bus	iness in at least two	o states?		Yes [] No	o [X]
16.1	If no, does the reporting entity assume reinsurance to domicile of the reporting entity?						Yes [] No	o [X]

FIVE-YEAR HISTORICAL DATA

		1 2023	2 2022	3 2021	4 2020	5 2019
	Balance Sheet (Pages 2 and 3)	2020	LULL	2021	2020	2010
1.	Total admitted assets (Page 2, Line 28)	543 614 331	740 507 952	683 378 987	619 182 017	499 695 483
2.	Total liabilities (Page 3, Line 24)					
3.	Statutory minimum capital and surplus requirement .					
4.	Total capital and surplus (Page 3, Line 33)					
٦.	Income Statement (Page 4)	104,000,000	100,027,220	140,200,002	100,707,022	170,720,001
5.	Total revenues (Line 8)	1 249 876 976	1 202 014 061	1 166 425 411	1 100 882 018	1 160 038 050
	Total medical and hospital expenses (Line 18)					
6. 7.	Claims adjustment expenses (Line 20)					
	Total administrative expenses (Line 21)					
8.	Net underwriting gain (loss) (Line 24)					
9.	Net investment gain (loss) (Line 27)					
10.	Total other income (Lines 28 plus 29)					
11.	Net income or (loss) (Line 32)					
12.		33,823,801	55,351,002	29,225,123	55,090,881	
	Cash Flow (Page 6)	00 500 040	(00, 400, 000)	445 000 707	100 000 170	400 700 000
13.	Net cash from operations (Line 11)	29,560,919	(66, 198,638)	115,093,727	139,929,170	120,768,229
	Risk-Based Capital Analysis	404 050 000	450 007 000	440,000,050	455 707 000	470 705 504
14.	Total adjusted capital					
15.	Authorized control level risk-based capital	25,965,987	22,356,357	22,512,434	15,203,445	25,652,318
	Enrollment (Exhibit 1)	212.122				
16.	Total members at end of period (Column 5, Line 7) .					
17.	Total members months (Column 6, Line 7)	3,847,998	4,518,984	4,864,236	4,737,356	4,685,438
	Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0					
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19.	Total hospital and medical plus other non-health (Lines 18 plus Line 19)				81.9	
20.	Cost containment expenses				1.7	
21.	Other claims adjustment expenses					
22.	Total underwriting deductions (Line 23)					
23.	Total underwriting gain (loss) (Line 24)	3.3	3.6	3.2	5.3	7.2
	Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24.	Total claims incurred for prior years (Line 17, Col. 5)	140 , 167 , 909	160,888,657	114,006,120	95,802,582	72,913,114
25.	Estimated liability of unpaid claims-[prior year (Line 17, Col. 6)]	159,855,632	178, 103, 948	125,527,599	100,370,821	84,863,772
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)					
27.	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)			0	0	0
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)			0	0	C
29.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)	0	0	0	0	
30.	Affiliated mortgage loans on real estate					
31.	All other affiliated					
32.	Total of above Lines 26 to 31	0	0	0	0	c
33.	Total investment in parent included in Lines 26 to 31 above.					

NOTE: If a party to a merger, have the two most recent years of this exhibit been restated due to a merger in compliance with the disclosure				
requirements of SSAP No. 3, Accounting Changes and Correction of Errors?	Yes [] N	No []
If no, please explain:				


SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS


Allocated by States and Territories


Activity	1	Allocated by States and Territories 1 Direct Business Only											
Septic S						3	4		6 Federal Employees Health	7 Life and Annuity			10
2. Astala AK N	4			(a)	Health					Other	Casualty	Columns 2 Through 8	Deposit-Type Contracts
3. AZDORB AZ N. N. S. S. S. N. S.													
4. Akanasa ARR M. S. Calorado CA M. S. Calorado													
6. Colorado CO R												0	
7. Connectant CT X X	5.		-									0	
B. District Of Country District Of Count												0	
9 Desired Columbia DC			-										
10 Finds													
11 Georgie GA X			-										
12 Hewei H N.													
14. Ilmois L	12.	•	-									0	
15 Indiana	13.	Idaho	ID	N								0	
16. 10 wa												0	
17. Kansas KS N													
18. Kentucky Y													
19. Louisians LA N. N. N. N. N. N. N. N													
20. Marine		-											
21													
23. Michigan MI N. 0 0 0 0 0 0 0 0 0		•	MD									0	
24													
25		-											
26. Missouri MO J													
27. Montans													
29 Nevada NV N N N N N N N N													
30. New Hampshire	28.	Nebraska	NE	N								0	
31. New Jersey NJ N	29.	Nevada	NV									0	
32 New Mexico		•											
33 New York		=											
34 North Carolina													
35 North Dakota												_	
37. Oklahoma													
38 Oregon	36.	Ohio	ОН	N								0	
39 Pennsylvania		Oklahoma	OK									0	
40		-											
41. South Carolina SC													
42. South Dakota SD												_	
43 Tennessee TN													
44. Texas TX N. O.													
46. Vermont VT													
47. Virginia VA N. <td< td=""><td>45.</td><td>Utah</td><td>UT</td><td>N</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>0</td><td></td></td<>	45.	Utah	UT	N								0	
48. Washington WA													
49. West Virginia WV N. 0		•							·····				
50. Wisconsin WI N.		-											
51. Wyoming WY .N. .0 52. American Samoa AS .N. .0 53. Guam GU .N. .0 54. Puerto Rico PR .N. .0 55. U.S. Virgin Islands VI .N. .0 56. Northern Mariana Islands MP .N. .0 57. Canada CAN .N. .0 .0 58. Aggregate Other Aliens .O		-											
52. American Samoa AS													
53. Guam													
55. U.S. Virgin Islands VI		Guam	GU									0	
56. Northern Mariana Islands													
Islands		-	VI	N					ļ			0	
57. Canada CAN N	56.		MP	N								n	
58. Aggregate Other Aliens OT XXX 0 1,218,739,999 0 0 0 0 1,218,739,999 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,218,739,999 0 1,218,739,999 0	57.												
59. Subtotal		Aggregate Other											
60. Reporting Entity Contributions for Employee Benefit Plans XXX 61. Totals (Direct Business) DETAILS OF WRITE-INS 58001 58002 XXX 58098. Summary of remaining write-ins for Line 58 from overflow page VXX XXX XXX XXX XXX XXX XXX X	EO												0
61. Totals (Direct Business) XXX 942,314,914 19,480 0 0 276,405,605 0 0 1,218,739,999 DETAILS OF WRITE-INS 58001		Reporting Entity Contributions for Er	nployee		542, 514, 914	19,480	0		210,400,605	0	0		0
DETAILS OF WRITE-INS 58001	61				942 314 914	10 /20	n		276 405 605	n	Λ		0
58001	01.			^^^	JTL, J 14, 314	13,400	U	U	210,400,000	U	0	1,210,100,000	U
58002	58001.			xxx									
58998. Summary of remaining write-ins for Line 58 from overflow page	58002.			XXX									
write-ins for Line 58 from overflow page	58003.			XXX									
58003 plus 58998)(Line 58		write-ins for Line 58 foverflow page	from	XXX	0	0	0	0	0	0	0	0	0
	58999.			XXX	0	0	0	0	0	0	0	0	0


ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED

















40.6


SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP PART 1 – ORGANIZATIONAL CHART


BCBSA Licensee

Regulated Insurance Company


Regulated BCBSA Licensee

ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED






⁵ Wellpoint Corporation holds a 2% interest in Highland Investor Holdings, LLC, and ATH Holding Company, LLC holds the remaining 98% interest.



BCBSA Licensee

Regulated Insurance Company Regulated BCBSA Licensee ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED Anthem Partnership Holding Company, LLC 81-3974489 90% 49% 75% 50% NAIC 16345 NAIC 14276 NAIC 14064 Wellpoint South AIC 16298 NAIC 16168 NAIC 16145 Community Care Health Plan of munity Care Health Plan o Wellpoint Delaware, Inc. Carolina, Inc. APC PASSE, LLC Amerigroup District of Amerigroup Mississippi, Inc. CCHAILC® (DE) Kansas, Inc. 14 (SC) (DC) 81-4626605 G0660 82-1853423 26-4674149 82-1800037 G0670 45-3358287 G0631 81-4131800 G0655 92-3489706 82-3062789 95% 50% 50% NAIC 15951 GR Health Solutions, LLC 11 NAIC 16553 Momentum Health Community Care Health Plan of (PA) AMH Health, LLC 9 Partners, LLC 10 Nebraska, Inc. 12 (NC) 84-4672692 G8477 47-5456872 G0310 83-2435050 G0652 82-4684953 NAIC 16774 NAIC 12812 AMH Health Plans of Maine Inc (PA) 30-0326654 G8478 84-4181695 G0653

- 7 Community Care Health Plan of Louisiana, Inc. is a joint venture 75% owned by Anthem Partnership Holding Company, LLC and 25% owned by Louisiana Health Service & Indemnity Company dib/a Blue Cross and Blue Shield of Louisiana (non-affiliate)
- ⁸ CCHA, LLC is a joint venture 50% owned by Anthem Partnership Holding Company,
 LLC and 50% owned by Colorado Community Health Alliance, LLC (non-affiliate)
- ⁹ AMH Health, LLC is a joint venture 50% owned by MaineHealth (non-affiliate) and 50% owned by Anthem Partnership Holding Company, LLC
- ¹⁰ Momentum Health Partners, LLC is a joint venture 50% owned by Anthem Partnership Holding Company, LLC and 50% owned by Blue Cross and Blue Shield of North Carolina (non-affiliate)
- ¹¹ GR Health Solutions, LLC is a joint venture 50% owned by Anthem Partnership Holding Company, LLC and 50% owned by Independence Blue Cross, LLC (nonaffiliate)
- 12 Community Care Health Plan of Nebraska, Inc. is a joint venture 95% owned by Anthem Partnership Holding Company, LLC and 5% owned by Blue Cross and Blue Shield of Nebraska, Inc. (non-affiliate).
- ¹³ APC PASSE, LLC (regulated entity) is a joint venture 49% owned by Anthem Partnership Holding Company, LLC and 51% owned by Arkansas Provider Coalition, LLC (non-affiliate).
- ¹⁴ Community Care Health Plan of Kansas, Inc. is a joint venture 90% owned by Anthem Partnership Holding Company, LLC, 5% owned by Blue Cross and Blue Shield of Kansas (non-affiliate) and 5% owned by Blue Cross and Blue Shield of Kansas City (non-affiliate).



OVERFLOW PAGE FOR WRITE-INS

Additional Write-ins for Assets Line 25

			Current Year					
		1	1 2 3					
				Net Admitted Assets	Net Admitted			
		Assets	Nonadmitted Assets	(Cols. 1 - 2)	Assets			
2504.	DOI fees recoverable	170,558		170,558				
2505.	Miscellaneous receivables	119,034	16,372	102,662	91,513			
2506.	Prepaid expenses	2,016,733	2,016,733	0	0			
2597.	Summary of remaining write-ins for Line 25 from overflow page	2,306,325	2,033,105	273,220	91,513			

Additional Write-ins for	Liabilities Line 23
--------------------------	---------------------

			Current Year					
		1	2	3	4			
		Covered	Uncovered	Total	Total			
2304.	Performance guarantee liability	212.945		212.945	513.295			
2397.	Summary of remaining write-ins for Line 23 from overflow page	212,945	0	212,945	513,295			